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Rebecca Zhangqiuzi Fan 
 ‘ Blocking mitochondrial fission protects against toxicity induced by α-
synuclein overexpression’ 
Abstract 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder with currently no effective neuroprotective or neurorestorative 
treatments available. Alpha-synuclein (α-syn) pathology is one of the key 
proteins involved in PD pathology, it has been found to induce mitochondrial 
dysfunction, yet the mechanism is not entirely understood. This thesis project 
tests the hypothesis that α-syn induces mitochondrial dysfunction through 
disruption of fission/fusion pathway. Using an inducible cell line, I 
successfully demonstrated that in a time-dependent manner α-syn 
overexpression induces mitochondrial fragmentation through disruption of 
fission/fusion dynamics, collapse of mitochondrial membrane potential, 
increased oxidative stress and impaired mitochondrial respiratory capacity. In 
addition, accumulation of protein aggregation was also observed due to 
impaired autophagy flux. More importantly, blocking the fission protein 
Dynamin Related protein 1 (Drp1) either genetically or pharmacologically 
confers protection against these abnormalities. Although further investigation 
is needed to better understand this protective mechanism, these results are 
consistent with our previous published data and those from other laboratories 
that Drp1 inhibition is a promising therapeutic target for PD. 
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1. Background
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1.1.     Parkinson’s disease  
Parkinson’s disease (PD) is a neurodegenerative disorder with selective and 
profound loss of dopaminergic neurons in the substantia nigra and is typically 
diagnosed by cardinal motor syndromes. The primary symptoms include resting 
tremor, rigidity (stiffness), bradykinesia (slowness of movement) and postural 
instability, although to date there are over 30 clinical symptoms recognised as 
fundamental features for the disease (Przedborski, 2017). Identification of the Lewy 
body, the intracellular lesion composed of proteins such as α-syn and ubiquitin, at 
post-mortem autopsy, is the primary pathological hallmark of the disease. PD is the 
second most common neurodegenerative disorder, and an epidemiological study 
(Dorsey et al., 2007, Dorsey et al., 2006) predicted the number of over 50 year olds 
with PD will increase to 8.7 million by 2030, doubling the approximate 4.1 million of 
2005. PD is known to be primarily caused by damage to the nigrostriatal 
dopaminergic pathway, yet the pathogenesis of this heterogeneous disease is not 
fully understood (Blesa and Przedborski, 2014) 
    It is believed that PD has existed since ancient times, and it made its first 
appearance in western medical literature in AD175, described as “shaking palsy” by 
the physician, Galen (Koehler and Keyser, 1997). However, the first collective 
definition for PD was established in 1817, when a London doctor James Parkinson 
published an article entitled "An Essay on the Shaking Palsy”. In this study, he 
described the six cases he came across during his own practice and from the 
neighbourhood. He characterised in detail the symptoms of this medical condition: 
involuntary tremors, difficulty with balance, and festination (“A propensity to bend the 
trunk forwards, and to pass from a walking to a running pace”) (Parkinson, 2002). It 
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was not until the 1960s that emerging evidence identified the biochemical change as 
lower levels of dopamine in PD brains, resulting from the loss of dopaminergic 
neurons in the substantia nigra, as summarised by Fearnley & Lee, which was later 
confirmed by Damier and colleagues (Fearnley and Lees, 1991, Damier et al., 1999). 
It was also during this period that Levodopa was first introduced to treat PD patients. 
Following this discovery, research on PD progressed remarkably over the years, with 
better understanding of the disease and effective treatments developed to control the 
symptoms. As more non-motor symptoms are documented, PD is more 
distinguished from motor parkinsonism, and it is generally considered as a collective 
term for multisystem neurodegenerative disorders. 
    Despite the remarkable progress in characterisation and understanding the 
disease, to date, there is no neuroprotective or neurorestorative treatment available. 
Five decades on since its introduction to PD treatment, Levo-Dopa (L-Dopa) remains 
the best and most common treatment despite the side effects including hypotension, 
abnormal involuntary movements, and problems with long-term treatment(Barbeau, 
1969). Better understanding of the pathogenesis process and finding potential new 
therapeutic treatments remains an important need. 
 
1.1.1. Sporadic and familial PD overview  
The topic of PD pathogenesis is complicated by the variations in clinical symptoms 
and disease pathology. Multiple risk factors have been identified, with ageing 
standing out as the number one risk factor for people over fifty. Although it would be 
easier to consider PD as ‘acceleration of ageing’, the difference in age-associated 
dopamine loss between individuals cannot be explained (Cannon and Greenamyre, 
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2013). In the early 1980s, a meperidine homolog called 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), was found to induce severe parkinsonism in drug addicts 
(Davis et al., 1979, Langston et al., 1983). The culprit was its metabolite 1-methyl-4-
phenylpyridinium (MPP+), a mitochondrial complex I inhibitor. This link and other 
neurotoxins and pesticides discovered later allowed researchers to look more closely 
into certain pathways that facilitate disease formation and progression. Meanwhile, 
the discovery of genetic mutations, especially those linked to early onset of the 
disease, implicated gene involvement that could be independent from ageing. All PD 
cases can be generally divided into two categories, those clearly linked to genetic 
mutations are recognised as familial PD and the rest termed as sporadic PD.  
 
Sporadic PD. Idiopathic PD or sporadic PD refers to all the disease conditions 
where no evident genetic mutation is found. About 90% of PD cases are sporadic, 
the remaining cases are caused by genetic mutations (Dawson and Dawson, 2010) , 
Efforts to better understand the aetiology of the disease have yielded a wide range of 
potential causes. However, the lack of direct evidence has prevented conclusive 
consensus being reached and therefore further investigation is required.- 
Nevertheless, environmental factors, such as exposure to certain organic 
compounds and heavy metals have been proposed to play a major role. Following 
the discovery of MPTP, decades of epidemiological study have identified a certain 
group of pesticides and other herbicides associated with PD including rotenone and 
paraquat (PQ) (Giasson and Lee, 2000, Priyadarshi et al., 2001, Tanner et al., 
2011b). Relevant to these observations, rural living has been associated with higher 
PD risk (Gorell et al., 1998). It’s well known that exposure to high dose of pesticides, 
even just once, could have lethal toxicity; however the link discovered between 
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chronic low dose exposure and PD development (Baldi et al., 2003) remains to be 
further explored. 
    Rotenone, for instance, is a mitochondrial complex I inhibitor commonly used as 
insecticide and pisticide (kills fish in lakes and reservoirs etc.). Rotenone has been 
associated with increased risk of developing PD (Tanner et al., 2011a, Kamel, 2013, 
Tanner et al., 2011b). Experimental rat models of this systemic exposure to the toxin 
have replicated many pathological features of the disease in humans including 
bradykinesia, postural instability, and/or rigidity, all linked to loss in dopaminergic 
neurons (Cannon et al., 2009, Betarbet et al., 2000). Comparing to rotenone, PQ is 
more well-documented in PD, as stronger links have been demonstrated from case- 
studies. PQ is a widely used herbicide for weed control, although it is banned in 
many countries including Europe, restricted usage is still permitted in the US. PQ 
shares structural similarities with MPTP, however, it does not have a direct inhibition 
effect on electron transport chain(Richardson et al., 2005) . Instead, it generates 
reactive oxygen species (ROS) through redox cycling. In addition, heavy metals such 
as manganese (Mn) and iron (Fe) have been linked to increased risk of developing 
PD (Fukushima et al., 2010, Dantzig, 2006, Uversky et al., 2001, Quadri et al., 2012, 
Roth, 2014).  
    Intriguingly, a common pathway of mitochondrial dysfunction has been identified 
for many of the environmental toxicants either through direct inhibition such as 
rotenone, or through indirect disruption such as ROS generation by PQ (Helley et al., 
2017b). Although this link, or alleged increased risk, might not serve as direct 
evidence for PD, several neurotoxin models have successfully displayed nigrostriatal 
damages and some of the behavioural phenotypes in rodent and primate models 
(Tieu, 2011, Bové and Perier, 2012). Interestingly, although some individual factors 
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on their own would not increase the risk by much, the combination with other factors 
could significantly increase the risk. For example, the combined exposure of PQ and 
the fungicide, Maneb have been found to increase the risk of PD by 75% in a case-
control study in California (Costello et al., 2009). In experimental models, the 
concurrent exposure of the two toxins have shown to induce significant neuronal loss 
in non-transgenic mice, and loss was further enhanced in transgenic mice 
expressing human α-syn (Desplats et al., 2012). Related to this, gene-environment 
interaction has received much attention in PD. Elevated α-syn levels, aggregation, 
secretion and spreading have been shown in different neurotoxin models such as 
rotenone, suggesting higher induction of the protein in response to the toxin 
exposure (Feng et al., 2006, Pan-Montojo et al., 2012a). 
 
Familial PD. Familial PD is distinguished from sporadic PD by a clear family history 
of the disease with an identified monogenic mutation. Approximately 30% of the 
familial and 3–5% of sporadic PD cases are caused by monogenic mutations, while 
the other remaining cases are classified as sporadic with unknown aetiology (Klein 
and Westenberger, 2012, Hernandez et al., 2016, Surmeier et al., 2017, Obeso et 
al., 2017). Familial PD can be caused by either autosomal dominant or autosomal 
recessive mutations. Although familial PD only makes up less than 10% of all PD 
cases, to date there are mutations in over 10 genes discovered in PD. The names of 
some major genes, their functions and mutations linked to PD are summarised in 
Table 1.1. 
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Table1.1 List of major mutations discovered to be associated with PD and the 
normal function of respective proteins (modified from (Helley et al., 2017b)) 
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Up to 
40% of 
familial 
and up 
to 10% 
of 
sporadic 
cases 
Multiple 
roles 
including 
cytoskeletal 
dynamics, 
vesicular 
transport, 
and 
autophagy 
Differ by 
populations and by 
mutation. 
p.G2019S shows 
penetrance 
sometimes 
estimated to be as 
low as 24%, the 
p.R1441 mutation 
is highly penetrant 
(95% at the age of 
75 yr) 
Funayama 
et al., 2002 
VPS35 PARK 
17 
16q1
1.2 
AD D620N 1% of 
familial 
and 0.2% 
of 
sporadic 
cases 
Part of the 
retromer 
cargo- 
recognition 
complex 
critical for 
the 
endosome- 
trans- Golgi 
High and age-
dependent 
penetrance (onset 
range: 34-68 
years) 
Vilarino-
Guell et 
al., 2011; 
Zimprich 
et al., 
2011 
CHCH
D2 
PARK 
22 
7q11
.2 
AD 10 
mutations 
(see 
Not 
available 
Activates 
gene 
involved in 
forming 
Not available Funayam
a et al., 
2015; 
Ogaki et 
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Koschmidd
er et al., 
2016) 
Complex IV 
of 
mitochondri
al 
respiratory 
chain 
al., 2015 
GBA N/A 1q21 AD >300 
mutations, 
L444P and 
N370S are 
most 
common 
Varies 
in 
different 
PD 
populati
ons but 
up to 
31% in 
Ashken
azi 
Jewish 
PD 
patients 
a lysosomal 
enzyme that 
catalyzes the 
breakdown 
of the 
glycolipid 
glucosylcera
mide 
(GlcCer) to 
ceramide 
and glucose 
7.6% at 50 years 
and 
29.7% at 80 years 
Tsuji et al., 
1987;  
Neudorfer 
et al., 1996 
Parkin PARK 
2 
1p35
-36 
AR ∼147 
exonic 
mutations 
77% 
familial 
EOPD 
and 10–
20% 
EOPD in 
Mitophagy Penetrance 
complete in 
individuals who 
have biallelic 
pathogenic variants 
Kitada et 
al., 1998 
 
PINK1 
 
PARK 
6 
 
6q25
.2-
27 
 
AR 
 
>60 
mutations, 
General 
>9%EOP
D 
Mitophagy Age-dependent, 
appears to be 
complete in 
individuals who have 
biallelic pathogenic 
variants 
 
Valente et 
al., 2004a 
DJ-1 PARK 
7 
1p36 AR >10 
mutations 
1–2% 
EOPD 
Has been 
proposed to 
protect cells 
from 
oxidative 
stress 
Penetrance for 
homozygous and 
compound 
heterozygous 
mutation carriers 
seems to be 
complete 
Bonifati et 
al., 2003 
ATP13
A2 
PARK 
9 
1p36 AR >10 
mutations 
Rare 
(foun
d in 
11 
famili
es) 
5 P-type 
ATPase 
polytopic 
lysosomal 
membrane 
protein 
variable 
penetrance 
Ramirez 
et al., 
2006; Di 
Fonzo et 
al., 2007 
FBXO
7 
PARK 
15 
22q1
2-13 
AR R378G, 
R498X, 
T22M, 
L34R 
Rare serve as 
molecular 
scaffolds in 
the formation 
of protein 
complexes 
Not available Shojaee et 
al., 2008 
PLA2
G6 
PARK 
14 
22q1
3.1 
AR R741Q, 
R747W 
and 
more 
Rare a 
phosphol
ipase A2 
enzyme 
Not available Paisan-
Ruiz et 
al., 
2009 
EOPD, Early-onset PD (Age at onset <50 years old); LOPD, Late-onset PD (Age at 
onset ≥ 50 years old); AD, Autosomal dominant; AR, Autosomal recessive; GW, 
Genome-Wide 
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    The first mutation discovered was alpha-synuclein (α-syn), before which PD was 
long considered to be a sporadic disorder. Soon after, mutations in a ubiquitin E3 
ligase, Parkin, was reported, in autosomal recessive parkinsonism with early onset. 
    In 2004, the mutation of a mitochondrial kinase PTEN-induced putative kinase 1 
PINK1 (encoded by PINK1) was found to induce early-onset PD (Valente et al., 
2004). Although PINK1 mutation is rare, accounting for less than 1% of all PD on a 
population basis with only 1-8% of PD patients (Klein et al., 2007) , the discovery of 
its mutation is significant. This direct link established the role of mitochondrial 
dysfunction in PD pathogenesis which has long be suspected since the identification 
of MPTP (Langston et al., 1983). PINK1, together with parkin, plays a vital role in 
mitochondrial quality control by mediating mitophagy. It is now a common knowledge 
that parkin proteins are selectively recruited onto depolarised mitochondria by PINK 
1 (Narendra et al., 2008) as an early event of the process. In addition, both PINK 1 
and parkin knockout mice have shown reduced mitochondrial respiration capacity in 
striatum despite no gross morphological abnormalities been observed (Palacino et 
al., 2004, Gautier et al., 2008). Over the years, other PD-linked mutations including 
α-syn have been discovered to also have an impact on mitochondria. For example, 
protein deglycase DJ-1 has also been reported to influence mitochondrial function 
and mitophagy indirectly through modulation of oxidative stress (McCoy and 
Cookson, 2011). DJ-1 is a cytosolic protein that belongs to the ThiJ/PfpI protein 
superfamily, fractionation study and immuno-electron microscopy (EM) have 
confirmed its mitochondrial localisation (approximately 25% of total DJ-1) (Zhang et 
al., 2005a).  
11 
    Leucine-rich repeat kinase 2 (LRRK 2/PARK8) is known to be the most commonly 
seen mutation in familial PD compared to other familial PD-linked genes, especially 
for certain ethnic backgrounds (Healy et al., 2008). Mutations in this gene are 
predominantly linked to autosomal dominant cases of PD, although they are also 
observed, at very low frequency, in other conditions such as AD, mostly as 
overlapping secondary pathologies observed at later stage of PD (Zhao et al., 2011). 
    Whilst monogenetic mutations only account for around 10% of all PD cases (de 
Lau and Breteler, 2006), the pathways affected by each of the mutations, whether 
shared by other mutations or not, provide insights into key factors that are also 
possibly disrupted in sporadic PD pathogenesis. With the increased interest in gene-
environment interaction, investigating genetic factors holds great value in helping us 
understanding the aetiology of sporadic cases. 
    The heterogenicity of PD indicates the complexity of PD pathogenesis. For familial 
PD cases so far, many different mutations from 18 specific chromosomal regions 
(known as PARK) have been identified, and the most well studied ones include: 
SNCA, PARK8/ LRRK 2, PARK6/PINK1, PARK2/parkin, and PARK7/DJ-1. Of these, 
the first two are accountable for autosomal-dominant forms of PD, whilst the other 
three are linked to autosomal recessive forms (Klein and Westenberger, 2012). As 
discussed above, the percentage of monogenic PD (disease caused by a single 
mutation) is very low, in many cases one mutation alone would not lead to disease 
pathogenesis, as within the same family carrying a certain mutation, not everyone 
would develop PD. On the other hand, through genome-wide association studies 
(GWAS), different mutations have been identified in sporadic PD cases, highlighting 
the importance of gene environment interaction (Mullin and Schapira, 2015) 
12 
 
    In this project I focused on α-syn for evaluating changes in mitochondria and 
autophagy pathways, as this specific protein is linked to both familial and sporadic 
PD (Dehay et al., 2015b). This suggests the possible common pathways involved in 
both familial and sporadic forms. Studying the pathological mechanism of this protein 
through genetic manipulation (mutation or overexpression) could potentially shed 
light on understanding disease pathogenesis in sporadic PD. 
 
 
1.2. Alpha-synuclein (α-syn) and PD pathogenesis 
Human α-syn protein is a 14 kDa pre-synaptic protein encoded by SNCA gene. 
Compared to the other two members of synuclein family (β- , γ-), α-syn is widely 
expressed in different tissues including pancreas, kidney, lung, skeletal muscle and 
heart, and predominantly in the brain (Lavedan, 1998). The structure of syn proteins 
is well conserved, with β-syn showing 61% match with α-syn (Goedert et al., 2017). 
The distinctive difference between these two proteins is the non-amyloid-β 
component (NAC) region specific to α-syn, which is responsible for the self-
assembling of the protein. In fact, only α-syn, not β-syn, is capable of forming 
aggregates, as shown in neurodegenerative disease models such as PD, Dementia 
with Lewy bodies (DLB) and multiple system atrophy (MSA). It is highly expressed in 
the CNS, with specific enrichments at presynaptic nerve terminals. Despite being the 
first mutation identified in PD, the exact function of this protein remains largely 
unknown. Nevertheless, it is commonly believed that α-syn is involved in synaptic 
vesicle trafficking and synaptic release. In 1997, it was found to be one of the main 
components of Lewy bodies, the intracellular protein lesion recognised as the 
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pathological hallmark of PD (Spillantini et al., 1997). Approximately at the same time, 
α-syn mutations were also discovered to be linked to PD, when a large Italian family 
was identified with a mutation of G209 substitution in the SNCA gene, resulting in a 
change of Alanine to Threonine at position 53. This resulted in an autosomal-
dominant form of PD with early onset. This is the first mutation discovered in PD, 
marking the start of familial PD research. Over the past few decades, as shown in 
Table 1.2, six different point mutations of α-syn have been reported: 
Table 1.2 Summary of α-syn mutations  
Mutation Gene 
Position 
Discovery Clinical features 
A53T 
(Ala53Thr) 
G209A (Polymeropoulos et al., 
1997a) 
Autosomal dominant early-onset PD 
A30P 
(Ala30Pro) 
G88C (Kruger et al., 1998) Autosomal dominant early- onset PD 
E46K 
(Glu46Lys) 
G188A (Zarranz et al., 2004a) Autosomal dominant 
H50Q 
(His50Gln) 
T150G (Appel-Cresswell et al., 
2013a) 
late-onset parkinsonism/ idiopathic PD 
G51D 
(Gly51Asp) 
A152G (Lesage et al., 2013)  Early-onset parkinsonian-pyramidal 
syndrome 
A53E 
(Ala53Glu) 
C158A (Pasanen et al., 2014) Atypical PD 
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    Although the proportion of genetic mutations is low in all PD cases, the presence 
of wild type protein in Lewy bodies links α-syn with common forms of the disease. In 
fact, higher levels of wild type α-syn can become toxic, as locus duplication and 
triplication of α-syn can also induce PD pathogenesis (Singleton et al., 2003a, 
Chartier-Harlin et al., 2004), with triplication leading to earlier onset and faster 
disease progression. 
    The association with both familial and idiopathic PD highlights the important role of 
α-syn in PD pathogenesis. The accumulation of either mutated or misfolded proteins 
inhibits autophagy and could lead to protein aggregation. Because α-syn protein is 
most abundant in the brain, for years it was believed that the aggregation seeds start 
in the brain. However, recent findings suggest synucleinopathies share a lot of 
similarity with a prion disease based on the observations that, α-syn aggregation can 
spread from one cell to another. The misfolded species could act as a ‘seed’ 
spreading from the gastrointestinal tract all the way up to the brain(Braak et al., 
2006) Although the mechanism of α-syn being transmitted between neurons is not 
entirely clear, several theories exists and are discussed in the following section. 
Nonetheless, this ties in well with the Braak Staging concept of the disease 
progression from brain stem to midbrain and up (Braak et al., 2003). And targeting 
the propagation of the toxic species might be the key to disease treatment at early 
stages. 
 
1.3. Pathogenic mechanisms of α-syn              
Since its discovery in PD, the role of α-syn in the disease has been studied 
extensively and different pathogenic mechanisms have been proposed. My study 
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focuses on mitochondrial dysfunction and impaired autophagy induced by α-syn 
resulting in neuronal dysfunction and neurodegeneration, as illustrated in Figure 1.1 
and further discussed in more details below.  
 
 
Figure 1.1 Pathogenic mechanisms of α-syn. When α-syn is misfolded under 
pathological conditions, this toxic form of the protein would induce 1) mitochondrial 
dysfunction, 2) autophagy inhibition, and 3) synaptic dysfunction. These three 
impaired pathways interlink and impact each other, leading to protein aggregation 
and impaired transmission, and eventually cell death. 
            
1.3.1. Synaptic dysfunction 
The term ‘synuclein’ originates from the observation of the co-localisation of this 
protein with both presynaptic terminals and the nuclear envelop, which has been 
confirmed by subsequent investigations (Yu et al., 2007). Although a certain portion 
has been found in the nuclear envelop and subcellular organelles, α-syn is mainly 
cytosolic and predominantly in terminals close to synaptic vesicles. In neurons, the 
presence of soluble α-syn at pre-synaptic terminals plays an important role in 
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synaptic plasticity and synaptic vesicle trafficking. It has been proposed that α-syn 
promotes SNARE complex assembly and regulates transmitter release (Bottner et 
al., 2015). The absence of α-syn has been shown to induce functional deficits among 
dopaminergic neurons in mouse model reflected by decreased DA release, whilst 
overexpression of this protein has also been demonstrated to have negative impact 
on neurotransmission (Abeliovich et al., 2000, Larsen et al., 2006). Both types of 
evidence support the theory that α-syn is a negative regulator for neurotransmitter 
release. However, although α-syn protein aggregation have been extensively 
characterised, the exact normal physiological function of this protein remains 
unclear. 
 
1.3.2. Prion theory----α-syn propagation 
The theory that α-syn is a prion-like protein is gaining attention in recent years. 
Although the Braak stage theory remains debatable, the spread of α-syn lesions into 
different brain regions as PD progresses is observed through post-mortem 
examinations of patient brains. As characterised by several independent groups, the 
early stage pathology progresses from caudal to rostral, and in the later stage 
spreads into limbic and neocortical regions (Braak et al., 2003, Dickson et al., 2010, 
Parkkinen et al., 2008). 
    The most direct and strong evidence of α-syn spreading came from post-mortem 
brain samples of PD patient brains who had gone through embryonic neuron 
transplantation. Decades after surgery, Lewy body structures were detected in the 
grafted neurons (Li et al., 2008b, Kordower et al., 2008). This raised the question of 
what was the mechanism behind the spread of toxic species and would stopping the 
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spread control disease progression. Ulusoy and colleagues have demonstrated in a 
rat model that overexpression of human α-syn in the lower brainstem does imitate α-
syn pathology in an upward propagation toward rostral regions, in a progressive 
manner. This long-distance spread recapitulates some disease features, reproducing 
a PD-like α-syn propagation pattern (Ulusoy et al., 2013). 
    Cell culture studies have revealed much more detail regarding the process. 
Emmanouilidou and colleagues have reported that, in cultured SH-SY5Y cells, 
overexpression of WT α-syn leads to exosome release of the protein, as both 
oligomeric and monomeric forms are both detected in collected conditional media 
(Emmanouilidou et al., 2010). On the other hand, nucleation seeds of WT α-syn in 
the media, once taken up by the cells using transfection reagent, increase 
intracellular α-syn phosphorylation and protein aggregation (Nonaka et al., 2010). 
    Several other possible inter-neuronal transmission pathways have also been 
proposed regarding the ‘seeding’ of misfolded protein. Apart from exosomal 
transportation (Danzer et al., 2012), some free-floating protein seeds can also 
directly travel through the plasma membrane of recipient cells or be taken-up 
through fluid-phase endocytosis or receptor-mediated endocytosis. Tunnelling 
nanotubes have also been shown to convey the transport between cells (Abounit et 
al., 2016). Intriguingly, the transmission has been proved to take place in neuron-to-
neuron (Desplats et al., 2009a),  neuron-to-astroglia (Lee et al., 2010) and neuron-
to-microglia manner (Kim et al., 2013a).  The transfer between different cell types 
highlights the limit of current therapies aimed at targeting dopaminergic neurons 
alone. Consequentially, a treatment that protects not only this specific cell population 
could offer greater therapeutic potential.  
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1.3.3.  Protein aggregation and impaired autophagy/lysosome 
One of the pathological hallmarks of PD is the formation of Lewy bodies, with α-syn 
being identified as one of the abundant components. Therefore, it is important to 
understand the formation of such protein inclusions for better understanding of PD 
pathogenesis. In cells, two major pathways exist to remove proteins and damaged 
organelles: the ubiquitin-proteasome system (UPS) which digests proteins through 
protease hydrolysis and lysosome-autophagy machinery. Both are the major 
pathways for the clearance of misfolded proteins. The UPS pathway was believed to 
be the dominant way of α-syn digestion for many years. However, in the past two 
decades, autophagy, alongside other proteinases including Calpain I, neurosin and 
metalloproteinases have all be found to be all involved in the protein turnover 
(Mishizen-Eberz et al., 2003, Kasai et al., 2008, Webb et al., 2003b). Nevertheless, 
the Greek word ‘Auto-phagy’, meaning self-eating, sums up the degradation system 
responsible for cleaning up misfolded proteins and dysfunctional organelles inside 
the cells. Theoretically, the term of autophagy is a collection of three different sub-
types: macroautophagy, microautopahgy and chaperone-mediated autophagy 
(CMA). While in a more general sense, autophagy is commonly used to describe 
macroautophagy, the most well-characterised type. In this study, I focused on the 
study of macroautophagy, due to the following reasons: first, the lack of evidence 
linking microautopahgy and α-syn; second, CMA only degrades monomer and dimer 
forms of α-syn, and third, above all, macroautuopahgy is the most prevalent form of 
autophagy. In addition, macroautopahgy has been reported to be impaired by α-syn 
(Winslow et al., 2010a), which could be potentially linked to α-syn release (Poehler et 
al., 2014).      Macroautophagy (hereafter referred to autophagy), involves targeted 
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protein/organelles being engulfed by autophagasomes, the cytosolic vesicles that will 
fuse with lysosome at a later stage to complete the process. 
    As illustrated in Fig. 1.2, autophagy flux involves the nucleation and elongation 
process of a membrane structure that forms vesicles termed autophagosome. In 
mammalian cells, this process involves a sequential activation cascade of a series of 
complexes. One of the main signalling pathways starts with mammalian target of 
rapamycin (mTOR), the master regulator of cell growth and proliferation. mTOR 
negatively regulates autophagy by binding the uncoordinated 51-like kinase  
(ULK)complex and inhibits its function(Hosokawa et al., 2009). Upon certain cellular 
stress such as starvation, mTOR function is blocked, ULK would then activate the 
Beclin1/PI3K complex. And this would lead to the membrane nucleation, forming 
autophagophore. Autophagophore then undergoes the elongation process which 
involves two important ubiquitin-like conjugations:  ATG12 firstly conjugates to 
ATG5, then binds to ATG16 non-covalently (Kuma et al., 2002); the second is the 
LC3 cleaved by ATG4 (becoming LC3-I), then conjugates to PE mediated by several 
proteins including the ATG12-ATG5-AGT16 complex (Walczak and Martens, 2013). 
Successful elongation leads to the double-membraned autophagosome. The 
autophagosome then goes on and fuse with lysosomes to form autolysosome, inside 
which waste proteins, toxins, and faulty organelles will be degraded by the enzymes 
within the lysosome.   
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Figure 1.2 Simplified diagram of autophagy flux. Autophagy process contains 
three overall steps: autophagosome synthesis (induction), autophagosome-
lysosome fusion and cargo degradation (completion). mTOR negatively regulates 
autophagy, and upon its inhibition, signal is sent to the ULK complex to initiate 
autophagosome formation. This activates the PI3K (Class III) /beclin-1 complex, 
which would then generate PI3P for nucleation. Through nucleation, the pre-
autophagic structure is formed, which then undergoes elongation. Membrane 
elongation process involves two ubiquitin-like conjugation complexes:  ATG12-5-
16L1 and the LC3-PE conjugate (LC3-II). The latter remains on the membrane 
when autophagosome biogenesis is completed, and therefore is commonly used 
as a autophagosome marker. Autophagosomes are then shuttled to lysosomes for 
autophagosome-lysosome fusion. After which lysosomal enzymes degrade the 
vehicles and cargos including receptor proteins such as p62, releasing amino 
acids for recycling, and the autophagy flux is completed. 
     
    In yeast, autophagy serves primarily as a starvation response, whilst in higher 
eukaryotic cells, it is involved in different physiological and pathological processes, 
and it’s dysfunction contributes to pathogenesis of many diseases (Lynch-Day et al., 
2012).     Autophagy levels vary between different cell types. In neurons, autophagy 
levels are relatively low yet vital to cellular function, with highly efficient progression 
from vesicle formation to degradation (Button et al.). Developments of PD 
pathogenesis research in the past two decades revealed the important role of 
autophagy dysfunction (Lynch-Day et al., 2012).  
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    It is now well established that α-syn inhibits autophagy (Winslow and Rubinsztein, 
2011) through the inhibition of lysosomal function. The same group also 
demonstrated that α-syn dislocates Atg9, a potent protein involved in 
autophagosome formation and lysosome trafficking (Winslow et al., 2010a). With two 
different processes inhibited by α-syn, it is possible that the mechanism might be 
more complicated than what have been revealed in literature. Nevertheless, the 
inhibition of autophagy would contribute to an accumulation of misfolded proteins 
building up leading to aggregation. Additionally, higher levels of α-syn would have a 
further inhibitory effect upon autophagy, forming the negative feedback loop.  
    Additional relevance to this study is the observation that autophagy has been 
shown to modulate the mitochondrial fission protein Dynamin related protein 1 (Drp1) 
turnover, with autophagy knockdown cells having higher Drp1 levels (Purnell and 
Fox, 2013). Therefore, in a model where autophagy is reduced, it is possible that 
there would be a change in the level and activity of Drp1, which potentially could be 
linked to excessive mitochondrial fission. On the other hand, autophagy has been 
discovered to be involved in synaptic formation in Drosophila (Shen and Ganetzky, 
2009). And because of the connections and similarities shared between endosome 
and lysosome, investigation into autophagy function could potentially find a link with 
synaptic vesicle trafficking, providing more insights on how α-synuclein interferes 
with multiple cellular pathways involving double lipid membrane systems. 
    Mitochondrial autophagy, commonly known as mitophagy, refers to the selective 
elimination of mitochondria through autophagy. As mentioned previously, upon 
mitophagy, Parkin are recruited by mitochondrial kinase PINK1 onto depolarised 
mitochondria, although the mechanism behind this selectivity is not entirely clear, 
with recent studies showing that PINK1 is capable of inducing mitophagy 
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independent of Parkin through ubiquitination (Lazarou et al., 2015). Although the 
exact factors marking the mitochondria for mitophagy remains unclear, enough 
evidence has shown that this process is selective instead of random. Scorrano et al 
demonstrated that to escape engulfment during autophagy, mitochondria elongates 
through Protein Kinase A (PKA)-mediated Drp1 inhibition (Gomes et al., 2011), 
suggesting size is one of the factors.  In accordance with this, it is widely 
acknowledged that fragmented mitochondria being cleared up by mitophagy serves 
an important role in mitochondria turnover, and this is vital for maintaining a healthy 
population of mitochondria. Different from normal mitochondrial fission that increases 
mitochondrial mobility and serves important physiological functions, excessive 
fragmented mitochondria are linked to mutation and dysfunction, this could be 
compensated via functional complementation (as discussed in later section) but only 
to a certain extent. When the threshold is reached, fusion of dysfunctional 
mitochondria with healthy mitochondria would only have a negative outcome, and 
therefore their segregation and removal prevent them from contaminating healthy 
mitochondria. Therefore, it is critical to maintain mitophagy within a certain range that 
would balance with mitochondrial dynamics and biogenesis, insufficient or excessive 
amounts would damage the balance. In pathological conditions where there is an 
excessive amount of mitophagy, whether as a result of mitochondria fragmentation 
or potentially altered selectivity, this will give rise to a loss of mitochondria, and could 
eventually leading to cell death (Choubey et al., 2011). Interestingly, on the other 
hand, in PD models with PINK1 or Parkin deficiency, different laboratories have 
reported accumulation of fragmented and dysfunctional mitochondria (Cui et al., 
2010a, Lutz et al., 2009). Therefore, the key is to maintain a healthy population of 
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mitochondria through selectively eliminating dysfunctional mitochondria before the 
ratio of dysfunctional ones reaches a threshold.  
    α-syn has been shown to induce mitochondrial fragmentation in multiple models in 
vitro and in vivo, and different theories have been proposed regarding the 
involvement of fission/fusion machinery in this process (Kamp et al., 2010, 
Nakamura et al., 2011, Gui et al., 2012). Fractionation study has confirmed the co-
localisation of α-syn with mitochondria (Shavali et al., 2008), and, more recent 
studies have revealed that α-syn binds to both inner membrane and outer membrane 
compartments (Robotta et al., 2014, Di Maio et al., 2016) that could potentially 
interfere with mitochondrial function. Point mutation G51D has been shown to 
increase membrane binding potential aside from the tendency for aggregation (Fares 
et al., 2014). α-syn has been reported to preferentially bind to the inner membrane of 
mitochondria (Kamp et al., 2010, Robotta et al., 2014), which would impact on the 
cristae structure and therefore mitochondrial respiration. Natural distribution of α-syn 
does not display specific enrichment on mitochondria, however, cytosolic 
acidification induced by oxidative or metabolic stress has been shown to significantly 
increase α-syn translocation onto mitochondria (Cole et al., 2008). Although the 
purpose of this stress-responsive phenomenon is inconclusive, many studies have 
shown that increased α-syn translocation is linked to increased mitochondrial 
dysfunction and mitophagy. 
    
1.3.4. Mitochondrial dysfunction 
Mitochondria are well known to be the ‘powerhouse’ of a living cell, yet they serve 
many other important roles involved in cell function and survival. A good example is 
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calcium (Ca2+) buffering, which is essential for maintaining the electrophysiological 
microenvironment.  In neurons, the communication between mitochondrial and 
endoplasmic reticulum (ER) is vital to synaptic function, as has been shown in AD 
model, the dysregulation of mitochondria with ER is linked to loss of synaptic 
function, mitochondrial dysfunction, and neuron cell death (Pera et al., 2017). In 
addition, it is the only organelle inside the cell carrying its own DNA outside nuclei. 
The mitochondrial DNA(mtDNA) contains about 16,500 base pairs of DNA consisted 
of 37 genes. 13 out of these 37 encode enzymes essential for oxidative 
phosphorylation in the electron transport chain complexes. Unlike nuclear DNA, 
mtDNA does not contain histone and lacks the proof-reading system during 
replication. As a result, mtDNA is more prone to mutation and damage. 
    The interest in mitochondrial involvement in PD has been increasing since the 
MPTP  incident, as discussed in section 1.1.1 (Langston et al., 1983). The active 
metabolite of MPTP upon oxidation, MPP+, was found to be a mitochondrial complex 
I inhibitor. As the largest macrocomplex in the electron transport chain 
(ETC)(illustrated in Figure 1.3), mitochondrial complex I has 46 subunits among 
which 7 are encoded by mtDNA. These 7 hydrophobic units, together with another 7 
nuclear-encoded subunits, are believed to form the “minimal essential” catalytical-
active composite (Keeney et al., 2006). Impaired catalytic activity of mitochondrial 
complex I has been identified in various tissues in sporadic PD patients despite the 
relatively selective cell death of neurons in substantia nigra (Parker and Swerdlow, 
1998). Another significance of the finding is that it supported the theory of inheritable 
mtDNA mutation (Wooten et al., 1997), and the non-Mendelian inheritance pattern 
displayed could potentially produce a more sporadic occurrence pattern of the 
disease. Over the years, the role of mtDNA mutation in PD was further explored by 
25 
 
multiple groups (Coxhead et al., 2016, Latsoudis et al., 2008, Hudson et al., 2013, 
Lin et al., 2012) and mtDNA deletion was also brought to attention by the studies of 
two separate studies (Kraytsberg et al., 2006, Bender et al., 2006). 
 
Figure 1.3 Mitochondrial Electron transport Chain. Mitochondrial electron 
transport chain consists of five complexes. Complex I: NADH dehydrogenase 
(NADH-CoQ reductase), Complex II: Succinate dehydrogenase, Complex III: 
CoQH2-cytochodrme C reductase, Complex IV: Cytochrome C oxidase, and ATP 
synthase. ATP synthesis is driven by a protonmotive force. The three proton 
translocating complexes (I, III and IV) act in parallel, generating proton current, 
whilst complex II reduces UQ to UQH2 without translocating protons. The proton 
current is utilised by ATP synthase, proton leak and several secondary processes, 
completing the proton circuit. ROS is generated as a result of the inability of ETC 
to completely reduce oxygen to water and the high oxygen consumption at the 
same time. Inhibition in complex I &III would significantly increase ROS generation 
and reduce ATP production, as in these situations the ‘leakage’ of electrons would 
lead to subsequent oxygen reduction to superoxide. 
 
    Since then a certain group of neurotoxins have been identified to inhibit 
mitochondrial respiration either through direct (Rotenone) or indirect inhibition 
(Paraquat).  Together with mutations discussed in previous sections, mitochondrial 
dysfunction is linked to both environmental factors and genetic models of PD, 
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implicating the common pathways in the disease development of both familial and 
sporadic PD (Parker et al., 1989, Exner et al., 2012, Helley et al., 2017b). 
    Over the years, many different groups have investigated how α-syn impairs 
mitochondrial function and contributes to pathogenesis in different disease models of 
PD. The mechanisms investigated can be summarised and assigned to three 
aspects: 
I. ETC inhibition; 
II. Reduction in mitochondrial biogenesis; 
III. Imbalanced mitochondrial fission and fusion. 
 
    The first two theories are well known and widely studied, whilst in recent years, 
there is an accumulation of evidence suggesting altered mitochondrial fission/fusion 
could be another mechanism. 
 
1.3.4.1. ETC inhibition 
The role of mitochondrial ETC dysfunction in PD has been extensively studied since 
the 1980’s, as reduced mitochondrial complex I activity observed in PD patients 
(Parker et al., 1989, Schapira et al., 1990, Janetzky et al., 1994). Although α-syn is a 
cytosolic protein, many studies have shown a small fraction of the protein found 
inside mitochondria, and the binding is enhanced when cytosolic acidity increases 
(Cole et al., 2008). This small amount of α-syn predominantly resides on inner 
membrane and has a direct impact on the electron transport chain. In addition, 
oligomeric forms of the protein has shown to preferentially permeabilise membrane 
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system modelling mitochondrial membranes rather than plasma membranes 
(Stefanovic et al., 2014). The accumulation of wild-type α-syn has been reported to 
be linked to reduced mitochondrial complex I activity, increased ROS production and 
depolarise mitochondria, especially the misfolded and aggregated forms (Devi et al., 
2008, Reeve et al., 2015). Mutations that facilitate protein aggregation, such as 
A53T, A30P, could possibly accelerate the process. This inhibition effect could relate 
to toxin inhibition of mitochondria that have been reported previously (Parker et al., 
1989, Janetzky et al., 1994, Chinopoulos and Adam-Vizi, 2001, Sherer et al., 2007).  
 
1.3.4.2. Reduction in mitochondrial biogenesis 
The peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a 
transcriptional coactivator which regulates energy metabolism. PGC-1α was first 
found in brown adipose tissue, which showed elevated expression upon cold 
induction as part of thermogenesis process (Puigserver et al., 1998). Soon after that 
it was found to stimulate mitochondrial biogenesis through uncoupling protein 2 
(UCP-2) and nuclear respiratory factors (Nrfs) (Wu et al., 1999), and is also highly 
expressed in other mitochondrial enriched tissues such as heart and skeletal 
muscles (Lehman et al., 2000, Lin et al., 2002). PGC-1α is a master regulator of 
many cellular pathways including mitochondrial biogenesis. The expression of PGC-
1α elevates the expression of Nrf 1 & 2, and PGC-1α would co-activate Nrf1 to 
trigger the expression of mitochondrial transcription factor A (mt TFA, commonly 
known as tFam). tFam will translocate from nuclei to mitochondria and activate 
mitochondrial DNA transcription and replication. In addition, PGC-1α protects 
mitochondria against oxidative stress by increasing Superoxide dismutase 1 (SOD1) 
and uncoupling (UCP) proteins. 
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    In 2010, a GWAS study conducted using 6.8 million raw data collected from nine 
genome-wide expression studiesPGC-1α gene expression was found to be 
supressed in PD patients, indicating a reduced number of mitochondria. Using an in 
vitro model, they found PGC-1α overexpression to be protective against A53T- α –
synuclein toxicity (Zheng et al., 2010). Although it should be noted that PGC-1α is 
the master regulator of several important pathways, for examples the SOD1 proteins 
also reduces ROS at cellular level which directly offers protection in many disease 
models, therefore the benefit of overexpressing PGC-1α cannot be simply credited to 
the improvement of mitochondrial function alone. 
 
1.3.4.3. Imbalanced mitochondrial fission and fusion 
Mitochondrial dynamics (refers to fission, fusion and movement) has been long been 
suspected to occur and was confirmed in 1990s with the combination of light 
microscope and fluorescent probes (Bereiter-Hahn and Voth, 1994). In recent years, 
the link between mitochondrial dynamics and α-syn has become a central question.  
    Mitochondria are highly dynamic organelles, whose many functions are 
determined by, and reliant upon, their size, structure and distribution. Increasing 
evidence suggests that α-syn affects mitochondrial morphology, which is linked to 
increased mitochondrial fragmentation and mitophagy (Choubey et al., 2011, Xie and 
Chung, 2012, Gui et al., 2012). These processes would eventually lead up to failure 
of energy metabolisms and neuronal cell death.   
    Maintaining mitochondrial morphology largely relies on the balance between 
fusion and fission. Fusion results in larger mitochondria and promotes energy 
production, it also rescues stress by sharing mitochondrial components, known as 
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functional complementation. This is very beneficial toward maintaining mitochondrial 
function, until the dysfunction reaches a threshold level of 80% (Youle and Van Der 
Bliek, 2012). Above this threshold, fusion between functional and dysfunction 
mitochondria results in the contamination of healthy mitochondria with unhealthy 
once, leading to the loss of function. Fission on the other hand can combat this 
problem by segregating highly damaged mitochondrial for mitophagy, which is vital 
toward mitochondrial quality control (Youle and Van Der Bliek, 2012). It is also 
needed to increase mobility of mitochondria, as it is much easier for shorter 
mitochondria to be transported to different cellular compartments and during cell 
division. Together, the fission/fusion dynamics ensures mitochondrial 
homogenisation(Mishra and Chan, 2014). In addition, the natural balance reached 
between continuous fission and fusion controls the size and number of mitochondrial 
tailored to the needs of the cell, determines mitochondrial intracellular connection 
and distribution. This plays a vital role toward bioenergetics, mitochondrial axonal 
transport in neurons and apoptosis. 
    Many different factors can affect mitochondrial fission/fusion, yet a key set of 
proteins have been identified as regulators for each of the processes, as illustrated in 
Figure 1.4.  
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Figure 1.4 Mitochondrial dynamics controlled by mitochondrial fission and 
fusion proteins (modified from review paper(Helley et al., 2017b, Tieu, 2014)) 
Mitochondrial fusion starting with the outer membrane fusion anchored by 
Mitofusin 1/2 (Mfn1/2), followed by inner membrane fusion mediated by Optic 
Atrophy 1 (OPA-1). Upon fission, the cytosolic protein Dynamin-related protein 1 
(Drp1) is recruited onto mitochondria, a process that can mediated by fission 
protein 1(Fis1), mitochondrial fission factor (Mff), and mitochondrial dynamics 
proteins of 49 and 51 kDa (MiD49 /51). All those anchor proteins are located on 
mitochondrial outer membrane. Through GTP hydrolysis, the GTPase Drp1 forms 
a oligomeric ring structure that provides restriction force to divide mitochondria. 
 
    In mammalian cells, mitochondrial fusion starts with the outer membrane fusion, 
mainly controlled by GTPases Mitofusin (Mfn) 1 and Mfn 2, followed by inner 
membrane fusion, directed by Optic Atrophy 1 (OPA-1). The location of these 
proteins is reflected by their function. On the other hand, upon fission, cytosolic Drp1 
is recruited by Mitochondrial fission 1 protein (Fis 1) and (Mitochondrial fission factor) 
31 
 
MFF, and mitochondrial dynamics proteins of 49 and 51 kDa (MiD49 /51) on the 
outer mitochondrial membrane and translocate onto mitochondria. Drp1 on 
mitochondria can assemble into dimers, tetramers and then form into an oligomeric 
ring-like structure. Drp1 is a GTPase, and GTP hydrolysis provides the main driving 
force for mitochondrial membrane constriction (Ingerman et al., 2005).  As the only 
non-mitochondrial member among the key fission/fusion machinery, any factors that 
influence the translocation of Drp1 could effectively alter mitochondria morphology 
without necessarily changing the protein level or inducing mutation. In addition, Drp1 
inhibition has proven to be more effective at blocking Drp1-mediated fission as Fis1 
or Mff inhibition does not completely stop Drp1 translocation, especially since the 
discovery of new anchor proteins Mid49/51 recruiting Drp1 in the absence of 
Fis1/Mff.  (Palmer et al., 2013, Osellame et al., 2016, Palmer et al., 2011), Therefore, 
Drp1 has been a target for disease models such as neurodegenerative disorders, 
which involve mitochondrial dysfunction with enhanced fission. Drp1 is the primary 
target in my study. 
 
Drp1  
Drp1 is a cytosolic GTPase involved in mitochondria fission regulation in mammalian 
cells (its yeast homolog is Dnm1). Drp1 and Dnm1 both contain four functional 
domains: An N-terminal GTPase domain, a dynamin-like middle domain, Insert B 
domain, and a GTPase effector domain (GED) located at the C-terminal.  
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    The GTPase domain is responsible for GTP hydrolysis and self-assembly of Drp1. 
As GTP hydrolysis results in Drp1 spiral decrease, this is generally considered to 
provide the driving force for mitochondria constriction during fission. The middle 
domain works together with the GTP domain which modulates intramolecular and 
intermolecular interactions of Drp1 proteins, enabling them to assemble into dimers, 
tetramers and higher structures. A dominant negative missense mutation A395D 
reported in a human case study has shown to interrupt mitochondrial fission, and in 
vitro investigation revealed that although they retained the ability to form tetramers, 
the A395D Drp1 failed to form higher structures and subsequent stimulation of 
GTPase activity. Moreover, Chang et al demonstrated that this mutation impairs the 
ability of the protein to co-localise onto mitochondria (Chang and Blackstone, 2007). 
The new-born who carried this mutation displayed abnormal brain development, 
optic atrophy, and dead at 37 days of age. Fibroblasts deprived from the patient 
displayed elongated mitochondria morphology (Waterham et al., 2007). The insert B 
domain is known as the variable domain, as it is less conserved among organisms. 
The exact function of this domain is not entirely clear, it’s known that Drp1 binds to 
 
 
Figure 1.5 Functional domains of Drp1 protein Drp1 contains four 
functional domains. The N-terminal GTPase domain (responsible for GTP 
hydrolysis during mitochondrial fission), the middle domain supports GTPase 
domain function, insert B/variable domain, and the C-terminal GTPase effector 
(GED) domain is essential for intra- and intermolecular domain interactions of 
Drp1, stimulating GTPase activity. 
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cardiolipin via GTPase domain, and Sesaki et al proposed that this insert B domain 
could provide specificity for the sites of Drp1-mitochondria binding during apoptosis 
(Sesaki et al., 2014). In addition, researchers have discovered that Drp1 is a 
substrate for reaction with nitric oxide (NO) species, and a recent study has shown 
MPP+ treatment elevates Drp1 level and it’s pro-fission phosphorylation at Ser616, 
both linked to NO production (Zhang et al., 2016).  
Post translational modifications of Drp1 and mitochondrial fission Unlike other 
key fission/fusion proteins, Drp1 is primarily a cytosolic protein with only 
approximately 3% colocalising with mitochondria as revealed by a percoll gradient 
fractionation study (Smirnova et al., 2001a). However, this small fraction on 
mitochondria is responsible for controlling mitochondrial fission, and factors 
regulating Drp1 distribution such as post translational modifications affect Drp1 
function and have an important impact on mitochondria fission.  
Phosphorylation One of the phosphorylation sites of Drp1 is Serine 367 in the GED 
domain (Chang and Blackstone, 2007). This phosphorylation by cyclic AMP-
dependent protein kinase (PKA) reduces Drp1 GTPase activity by blocking 
intramolecular interaction, and reducing Drp1 translocation onto 
mitochondria.(Chang and Blackstone, 2007). In addition, the overexpression of a 
phospho-mimetic mutation S637D resulted in elongation of mitochondria (Cereghetti 
et al., 2008). Yet this elongation effect is less prominent than the overexpression of a 
well characterised mutation K38A, which depletes GTPase activity to undetectable 
levels (Chang and Blackstone, 2007). S367 phosphorylation is reversed by 
calcineurin, a Ca2+-dependent phosphatase, which facilitates Drp1 translocation onto 
mitochondria. 
34 
 
    In contrast to S367 phosphorylation, Erk-mediated phosphorylation at Serine 616 
increases Drp1 translocation onto mitochondria and facilitates mitochondrial fission. 
This phosphorylation has been shown to be induced upon cold exposure or by 
oncogene Ras in cancer models. Interestingly, when researchers tested its mimetic 
mutation S616D, GTPase activity was not affected and mitochondrial morphology 
remained normal. This is the outcome of unaltered GED domain interactions with 
GTP-binding/middle domain, suggesting Ser616 phosphorylation affects Drp1 
function through other mechanisms (Taguchi et al., 2007). Other post-translational 
modifications include: SuMOylation, which is a transient and reversible process led 
by an enzyme belongs to the ubiquitin family called small ubiquitin-like modifier 1 
(SUMO 1). Prudent and colleagues have discovered that MAPL-dependent 
SUMOylation stabilises Drp1oligomeric assembly on mitochondria during apoptosis 
(Prudent et al., 2015). Ubiquitination is generally considered as a protein interaction 
motif that targets protein for proteasome degradation. Parkin, the E3 ubiquitin ligase 
involved in mitochondrial autophagy (mitophagy), has been shown to promote 
Drp1ubiquitination for proteasomal degradation (Wang et al., 2011a). S-
nitrosylation refers to the reversible process of NO forming S-nitrosothiols (SNO) 
with cysteine residues of target proteins through redox reactions. Reactive nitrogen 
species (RNS) is one of the main sources of oxidative stress commonly seen in 
neurodegenerative diseases. Cho and colleagues have demonstrated, in an AD 
model, the role of s-nitrosylation of Drp1 on β-Amyloid linked neuronal injury linked to 
mitochondrial fission (Cho et al., 2009a). 
    Apart from regulating mitochondrial fission as part of fission/fusion machinery, 
another function of Drp1 is in apoptosis. Mitochondrial fragmentation is one of the 
features for apoptosis. As in healthy cells, functional mitochondria elongate through 
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increased Drp1 inhibition at Ser637 to bypass mitophagy (Gomes et al., 2011), whilst 
the fragmented ones are engulfed by autophagy machinery. Upon apoptosis, 
however, Drp1 translocates onto mitochondria binding to Bax, inducing Bax/Bak-
mediated mitochondrial membrane permeabilisation and triggering cytochrome c 
release.(Cassidy-Stone et al., 2008). Moreover, a recent study has shown that 
through MAPL SUMOylation, Drp1 also stabilises ER/mitochondria contact and 
signalling, facilitating Calcium flux and remodelling of cristae structures required by 
programmed cell death(Prudent et al., 2015) 
    In short, any dysregulation in Drp1, whether through expression, post-translational 
modification, or other mechanisms that impact protein distribution and/or activity, 
would disrupt mitochondrial homeostasis, and further impact cell function and 
viability. 
 
Role of Drp1 and mitochondrial dynamics in neurodegenerative diseases 
Compared to other cell types in the brain, neurons are more susceptible to 
mitochondrial deficits due to their high energy demand, complex cell morphology and 
specialised functions including synaptic activity. Synaptic loss occurs before cell 
death and is now recognised as early event in neurodegenerative disorders including 
PD. Synaptic formation and plasticity are linked to Ca2+ buffering and ATP 
production by mitochondria being transported to the terminals.  
    Drp1 is essential for synaptic formation both in vitro and in vivo (Ishihara et al., 
2009, Li et al., 2008a), however hyperactivation of Drp1 has been shown to induce 
neuronal damage (Nakamura et al., 2010). Indeed, aberrant mitochondrial dynamics 
has been observed in different neurodegenerative disease models PD, Alzheimer’s 
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disease (AD), and Huntington’s disease (HD) and Amyotrophic Lateral Sclerosis 
(ALS) (Cho et al., 2009b, Burte et al., 2015). Excessive fission associated with Drp1 
has been implicated in both cell culture and animal models of PD (Filichia et al., 
2016b, Rappold et al., 2014, Wang et al., 2011b, Cui et al., 2010a, Bido et al., 
2017b), AD (Wang et al., 2009, Manczak et al., 2011), HD (Shirendeb et al., 2011, 
Song et al., 2011, Manczak and Reddy, 2015), and ALS (Song et al., 2013, Xu et al., 
2010).   
    In PD, studies have been done in both genetic mutations and environmental toxin 
models targeting Drp1. For instance, in vitro, our laboratory described in a PINK 1 
mutation model the protective effect of blocking Drp1 with the putative inhibitor mdivi-
1, Drp1-knockdown and dominant negative (K38A) transfection (Cui et al., 2010a). 
Qi and colleagues applied a Drp1 peptide inhibitor P110 to demonstrate the 
protection against MPP+ (Qi et al., 2013b). 
   There are also emerging in vivo studies showing neuroprotection offered by 
inhibition of Drp1. Our laboratory reported in 2014, as a follow-up study to the in vitro 
work, blocking Drp1 showed significant protection in both PINK1-/- and MPTP 
mice(Rappold et al., 2014)  
 
α-syn and mitochondrial dynamics, is Drp1 the key? Some studies have shown 
that α-syn induces mitochondrial fragmentation, although several different theories 
exist regarding the process. Using model membrane system, Kamp and co-workers 
reported that α-syn inhibits membrane fusion. Co-expression of wild-typ PINK1, wild-
type parkin, wild-type DJ-1, but not the mutations linked to PD, showed protection 
(Kamp et al., 2010).The authors claimed the fragmentation is independent of the 
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fission/fusion machinery, despite the fact that they observed less fragmentation 
induced by α-syn when promoting fusion or inhibiting fission.  In 2011, Nakamura 
and colleagues raised the theory that α-syn drives mitochondrial fission through 
direct interaction with mitochondrial membrane. In a similar vein as the previous 
study, they reached the conclusion that this is independent of Drp-1 mediated fission 
even though they reported less mitochondrial fragmentation with Drp1-K38A 
transfection.(Nakamura et al., 2011). A year later, Gui et al showed that α-syn 
induced mitochondrial fragmentation is linked to Drp1 through ERK pathway, and 
blocking Drp1 was protective(Gui et al., 2012).  
    Drp1 has been studied in many different disease models and has become a topic 
of great interest for targeting mitochondria fission, as blocking Drp1 is the more 
direct and efficient way. This is because Fis1, Mff and MiD49/51 are receptor 
proteins that act as anchor proteins for Drp1 recruitment (Osellame et al., 2016, 
Palmer et al., 2013). Blocking Drp1 function is upstream of these proteins and 
therefore more efficient. 
    Although debate remains whether blocking Drp1 acts protectively through 
mitochondria in α-syn models. Previous studies proposed that α-syn induced 
mitochondrial fragmentation independent of fission/fusion machinery (Kamp et al., 
2010, Nakamura et al., 2010). However, these investigators failed to discuss that 
there was a clear attenuation in fragmented mitochondria induced by α-syn in cells 
with Drp1 inhibition compared to those overexpressing α-syn alone (Kamp et al., 
2010). In contrast to the above studies, other laboratories reported that mitochondrial 
fragmentation induced by α-syn is mediated by Drp1 (Gui et al., 2012, Choubey et 
al., 2011) .  In collaboration with another laboratory, we recently reported that 
blocking Drp1 using mdivi-1 is highly protective in a rat model of α-syn-A53T 
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mutation (Bido et al., 2017c). We demonstrated that mdivi-1 attenuated 
neurodegeneration, protein aggregation and locomotor impairment. However, some 
critical questions remained from that study. First, mdivi-1 was used to block Drp1 
function (Bido et al., 2017a). Although this inhibitor has been widely reported to 
produce effects consistent with blocking mitochondrial fission and GTPase function 
of Drp1 (Smith and Gallo, 2017b, Manczak et al., 2019), questions have been raised 
whether this inhibitor blocks Drp1 function (Bordt et al., 2017a). Second, α-syn-A53T 
mutation was used to model PD. Given that this missense mutation is rare and 
responsible for a very small fraction of PD cases, the significance of that study in 
relation to sporadic PD needs to be validated in models with wild-type (WT) human 
α-syn. Third, to date, Drp1 is commonly referred to as a “mitochondrial fission” protein. 
However, as mentioned previously, most of Drp1 resides not on mitochondria, but 
elsewhere in the cell. Indeed, a previous study estimated that only about 3% of Drp1 is 
localized to mitochondria under normal physiological condition (Smirnova et al., 2001b). 
Although under pathological condition, post-translational modifications such as 
phosphorylation of Drp1 at S616, would induce its translocation to mitochondria, a 
significant portion most likely still remains in the cytosol. It is critical to investigate 
additional protective mechanisms of this protein. My project was designed to address 
these three issues 
    
 
 
1.4. Project hypothesis and aim 
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Rationale: It is well established that mitochondrial dysfunction plays a role in PD. α-
syn point mutation and overexpression are both linked to mitochondrial dysfunction, 
which contributes to synucleinopathy. Despite being the first protein identified to be 
associated with PD and therefore being studied for many years, a great deal remains 
to be understood regarding how α-syn impairs mitochondria function. As discussed 
in the introduction, several mechanisms have been proposed regarding how α-syn 
mutation/overexpression facilitates PD formation. However, these pathways are not 
mutually exclusive, and one key element that potentially links all these mechanisms 
together is mitochondrial function (Helley et al., 2017b), as illustrated in Fig.1.6 
below. Understanding how α-syn leads to mitochondrial dysfunction could have high 
clinical potential. 
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Figure 1.6 Common pathogenic mechanisms induced by α-syn  . 
Mitochondrial dysfunction, induced by α-syn multiplications or mutations, results in 
a cascade of interconnected cellular dysfunction. Increased mitochondrial fission 
and fragmentation can initiate apoptotic cell death by inducing cytochrome C 
release. ATP-dependent processes such as autophagy would be impacted, 
resulting in reduced autophagic clearance of damaged proteins and organelles. 
This process is also sensitive to ROS. The multiplications and mutations of α-syn 
can also lead to increased ROS, which has the capacity to promote the formation 
of toxic oligomers and protein aggregates, impair ubiquitin proteasomal system 
function. ROS can also impair mitochondrial function, which in turn produces high 
mitochondrial ROS and further increases oxidative stress. In addition, increased 
ROS facilitates protein aggregation which further inhibits autophagy and Ubiquitin-
Proteasome system. As illustrated, all these mechanisms cross-talk and culminate 
in neurodegenerative processes in PD. (Modified from (Helley et al., 2017b) 
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The overall hypothesis of this project is that α-syn overexpression induces 
mitochondrial fragmentation and dysfunction through excessive fission, 
results in oxidative stress, impair autophagy flux, and protein aggregation. 
Furthermore, blocking Drp1 is protective. 
The following three aims were designed to test this hypothesis: 
1. Determine the effects of α-syn on mitochondrial morphology and function, 
oxidative stress, protein aggregation and autophagy mediated through mitochondrial 
fission. 
2. Evaluate the effects of blocking Drp1 on mitochondrial fragmentation and 
dysfunction induced by α-syn. 
3. Assess the impact of Drp1 inhibition on autophagic impairment and 
accumulation of aggregated protein induced by α-syn. 
. 
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2. Materials and Methods 
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2.1 Experimental models  
Several cell lines were selected in this study to address specific questions, a rat 
model is also used for investigating synaptosome function as part of a related 
project. All models discussed in this thesis are summarised in the table below: 
 
Table 2.1 Summary of different experimental models used in this study 
Model Origin Purpose Reference 
N27 cells with 
inducible human 
α-syn expression  
E12 rat 
mesencephalic 
tissue, immortalised 
with SV40 vector. 
Inducible cell line 
was generated by 
stable transfection of 
ecdysone inducible 
system containing 
SNCA 
Study the effects of 
α-syn expression 
over time in a more 
controlled manner 
N27 cell line 
(Prasad et al., 
1994) 
Inducible 
system 
method  
(Cui et al., 
2010a) 
Luhmes cells human 
mesencephalic-
derived cell line 
MESC2.10. 
immortalized with v-
myc retroviral vector. 
complementary 
model for rat 
dopaminergic cells 
(Lotharius et 
al., 2002) 
 
HeLa autophagy 
reporter cells 
Derived from cervical 
cancer cells of 
Henrietta Lacks 
Monitor autophagy 
flux by providing 
autophagosome and 
autolysosome levels 
HeLa cell line 
(GEY, 1952) 
Sprague Dawley 
rats  
An outbred 
multipurpose breed 
of albino rat, first 
came from Sprague 
Dawley farms in 
1979 
As an in vivo model 
for studying the 
effect of α-syn via 
AAV-delivery. Rats 
provide more striatal 
synaptosomes than 
mice. 
(White WJ, 
1998) 
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N27 cells with inducible human α-syn expression.  Inducible α-syn expression 
cell line was generated by stably transfecting rat dopaminergic neural cell line N27 
with ecdysone inducible system (Agilent, Complete Control Inducible Mammalian 
Expression System) containing human α-syn (see Figure 4 below) in the same 
manner as described in our previous publication (Cui et al., 2010a). α-syn inducible 
expression is stimulated by the addition of Ponastrone A (PonA), an ecdysone 
homolog compound. 
 
 
    The 
ecdysone-
inducible 
system 
consists of 
two 
vectors: 
the 
receptor 
vector 
pERV3 and 
the expression vector pEGSH modified from The Complete Control® Inducible 
Mammalian Expression System (Stratagene, LaJolla, CA). As illustrated in Fig. 2.1, 
the pERV3 vector contains an expression cassette from which the VgEcR and RXR 
proteins are constitutively expressed, and a neomycin-resistant gene for selection. 
 
   
Figure 2.1 Inducible expression of human α-synuclein in rat 
dopaminergic N27 neuronal cells.  The expression of SNCA is 
suppressed by co-repressors at VgEcR. Upon PonA induction, co-
repressors are released, and coactivators are recruited, resulting in 
gene activation via the minimal heat shock promoter (mHSP).   
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The pEGSH vector is inserted with the gene of interest, and in this case, SNCA 
(gene encoding α-syn), which is controlled by PonA-inducible expression cassette. 
Cells were firstly transfected with pERV3 receptor vector, selected by the addition of 
G418, and cells stably expressing pERV3 were then transfected with pEGSH vector 
containing full-length human SNCA gene and selected with Hygromycin B.  
    To select cells with high expression of α-syn, stable cells were incubated with 
SMARTFLARE human SNCA-Cy3 mRNA probe (Millipore, SF-1254) overnight. This 
non-toxic probe was taken up by living cells through endocytosis, it recognised and 
bound to α-syn mRNA produced inside the cells. And when this occurs, the 
fluorescence quenching sequence was released and Cy3 signal was activated. For 
sorting, cells were treated with PonA (or ethanol as control) for 24h, with probe 
(200nM) added 16h prior to sorting. On the day of sorting, cells were trypsinised, 
centrifuged (X1000g, 3min) to pellet, and re-suspended in sorting buffer containing 
PBS+1%FBS+20U/ml DNase I + 25mM HEPEs (1ml sorting buffer were used for 2-
3million cells). The suspension was then run through a cell strainer snap cap with 
polystyrene tube attached (BD Falcon™ 352235) by gravity. The tube was then 
carefully loaded to a FACSAria II, and sorted using FACS Diva 6.1.3 software 
channel PE-A. Two cell populations were collected: P1 (small fraction of cells with 
high α-syn expression) and P2 (larger inducible population with lower α-syn 
expression). Cells were collected in a tube pre-loaded with 1ml RPMI+20%FBS. The 
collected solutions were diluted into 10ml RPMI+20%FBS+P/S, span for 5min at 
1000rpm, and the pellets were then re-suspended in RPMI+20%FBS+P/S, 
transferred into a T25 tissue culture flask, incubated at 37°C overnight to attach. At 
least 48hrs were allowed for cells to recover before being changed back to complete 
medium. Inducible cells were labelled by human α-syn mRNA, as SMARTFlare live 
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mRNA probes (Millipore) tagged with Cy-3 that specifically recognises human α-syn 
mRNA were used. Probe up-take was confirmed by confocal microscopy with phase 
contrast (shown in Fig 3.1) 
    Cells were maintained in RPMI 1640 +10% FBS+G418 (500µg/ml) + hygromycin 
B (200µg/ml) (complete medium). α-syn expression upon PonA induction was 
confirmed by immunostaining and western blot. The level was characterised at 
different time points with different PonA doses for comparison (see result section), 
with 20μM PonA and 48h chosen for the assessment of mitochondria morphology 
and function. 
 
N27 cell differentiation development. To test whether the N27 cells could be 
differentiated into functional dopaminergic neurons, a few differentiation conditions 
were tested by adding different concentrations of Dibutyryl cyclic-AMP (dbcAMP, 
Sigma) and/or DHEA (sigma). Cells were differentiated up to 5 days, during which 
time the survival and morphology of the cells was tracked, and light contrast pictures 
were taken using a Leica microscope (see Appendix). The expression of synaptic 
markers (synapsin 1 and PSD 95) were tested using immunocytochemistry. 
 
LUHMES cells. The Lund human mesencephalic LUHMES cell line (ATCC® CRL-
2927™) were purchased from Millipore. It is a subclone of the tetracycline-controlled, 
v-myc-overexpressing human mesencephalic-derived cell line MESC2.10. 
Differentiated LUHMES cells expresses mature dopamine-like neuron features both 
morphologically and biochemically. 
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    Cells were maintained in complete growth media containing DMEM/F-12 +1% N-2 
supplement (Gibco-Invitrogen 17502-048) + 40 ng/ml b-FGF (basic recombinant 
human Fibroblast Growth Factor; Gibco-Invitrogen 13256-029), with b-FGF always 
added fresh right before use. All cell culture surfaces were sequentially pre-coated 
with 50 µg/mL poly-L-ornithine at room temperature overnight (Sigma, P-3655), and 
then with 1 µg/mL Human Fibronectin (Sigma, F-0895) at 37°C for 3 hours. Three 
rinses with ddH2O were used in between to wash away excessive coating reagents, 
and all surfaces are left in hood to dry. Coated cell culture vessels were either used 
right away or stored in fridge (4°C) for up to a week before used. Cells are 
subcultured every 2-3 days. 
    For differentiation, bFGF in complete growth medium were replaced with 
tetracycline (1μg/ml, diluted 1:1000 from 1mg/ml stock), GDNF (glial cell line-derived 
neurotrophic factor, 2ng/ml, diluted 1:1000 from 2μg/ml stock), and db-cAMP (1mM, 
diluted 1:100 from 100mM stock). Cells were differentiated up to 10 days and were 
plated for experiment at Day 2 of differentiation to control the cell number. 
 
HeLa autophagy reporter cells. A stable autophagy-monitoring cell line generated 
from Hela cells was kindly provided by Dr Shouqing Luo (Plymouth University). 
These cells were stably transfected with ptfLC3 plasmids, expressing rat LC3 fused 
to mRFP and EGFP (addgene) as indicators for autophagy flux. Stable cells were 
maintained in DMEM + 10%FBS + G418 (100µg/ml) + 1%P/S 
(Penicillin/Streptomycin). 
 
2.2 Cell transfection and treatments 
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Plasmid transfection. For all cell lines culture experiments apart from the LUHMES 
cells, plasmid transfections were carried out using either Lipofectamine 3000 or 
jetPRIME™ DNA and siRNA Transfection Reagent (Polyplus transfection), optimised 
following the guidance of manufacture’s protocol. For 24-well plate, 0.3ug of plasmid 
were used and for 6-well plate 0.75ug plasmid were used per well. 
    For lipofectamine transfection, an equal volume of Opti-MEM was used to mix with 
DNA plasmid and Lipofectamine Reagent, incubated 5min separately before being 
mixed together for another 15min of incubation. The mixture was then added to cells 
(in Opti-MEM) in a dropwise motion. 200µl of Opti-MEM complex was added per well 
for 6 well plates and 50µl for 24 well plates. 
    For the jetPRIME system, plasmids were diluted into jetPRIME Buffer (50 µl for 24 
well plate and 150 µl for 96 well plates), followed by 10s of vortexing to mix and a quick 
spin to collect everything at the bottom. Then jetPRIME Reagent (2X of plasmid 
amount v/w) was added to the complex, mixed by vortexing and incubated at room 
temperature for 15min. The complex was then added in a dropwise motion to cells 
maintained in normal culture media without antibiotics.Drp1 knockdown (siRNA). 
Pre-designed siRNA against rat dnm1l and human DNM1L (gene encoding Drp1) were 
purchased from Dharmacon Research, Inc. SMARTpool: siGENOME Rat Dnm1l 
siRNA was used for the N27 cells and SMARTpool: siGENOME Human Dnm1l siRNA 
was for HeLa cells. Each of this product is a mixture of four individual siRNA duplexes 
that target four separate sequences of the gene to maximize efficiency of gene 
silencing. To enhance transfection efficiency, an “in-tube” transfection procedure (Cui 
et al., 2010b) was used with the following modifications: Cell suspension (80,000-
100,000cells/ml) were mixed with jetPRIME™ DNA and siRNA Transfection Reagent 
(Polyplus-transfection®SA). For every 500μL of cell suspension (RPMI +10% FBS), 50 
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μL of jetPRIME buffer and 2 μL jetPRIME reagent were used. Cells were plated and 
left in transfection medium overnight, then media was changed the following day. 
Gene silencing efficiency was confirmed using western blot, with 10nM of siRNA 
achieving 75-90% knockdown compared to scrambled control (siGENOME Non-
Targeting siRNA Control Pools, Cat# D-001206, Dharmacon Inc) after 48h.  
 
Mdivi-1 treatment. For blocking mitochondrial fission through pharmacological 
approach, the putative Drp1 inhibitor 3-(2,4-Dichloro-5-methoxyphenyl)-2,3-dihydro-
2-thioxo-4(1H)-quinazolinone (mdivi-1) was applied. mdivi-1 (stock prepared in 
DMSO) was diluted in cell culture media to a working concentration of 10 μM. 
 
2.3 Cell viability assessment 
MTT cell viability assay. Cells were plated in 96-well plate at 5000/well-10,000/well 
depending on the treatment time and incubated overnight for attachment. Cells were 
treated with PonA the next day and incubated for up to 72h. On the day of assay, 
25μl of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) was 
added into each well, incubated in the dark at 37°C for 3 hours, followed by the 
addition of 100μl of MTT lysis buffer. The plate was then left overnight for the 
crystals to dissolve. Plate reading was done the following day after confirming that all 
the crystals were dissolved, and optical density at 562nm was measured using a 
Genois one plate reader. 
 
Calcein AM cell viability assay Calcein, AM (Invitrogen,1mg/ml in DMSO) was 
purchased from Thermo Fisher Scientific. . Working solution (2µg/ml) was made up 
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in PBS each time prior to experiment. N27 cells were grown in flat bottom 96-well 
plates. Upon assay, cells were washed with warm dPBS by replacing half the volume 
of media with dPBS and leave 50µl PBS in each well.100µl Calcein solution was 
then added to each well and the plate was incubated in dark at room temperature for 
1 h. Fluorescence signal was quantified using Synergy H1 Hybrid Reader ( Ex/Em 
494/520).     
.  
2.4 Immunostaining, Imaging and Immunoblotting 
Immunofluorescence. For imaging, cells were grown on borosilicate cover slips 
pre-coated with poly-D-lysine (0.1mg/ml in PBS, at room temperature overnight). The 
plating density varied between 50,000 and 100,000, depending on different 
treatment time points. Upon fixation, cells were incubated with 4% Formaldehyde 
(Thermo Scientific™ Pierce™ 28028, 1 in 3 diluted into warm cell culture media from 
16% solution) at 37°C for 20 min. The fixative was then washed away by 3 x 5min 
washes with PBS, after which the samples proceed to blocking with PBS containing 
4% normal goat serum and 0.1% Triton-X. Samples were incubated with primary 
antibody solution (please refer to Table 2.2 for a list of antibodies and dilutions used) 
overnight at 4°C on a slow shaker. The next day, primary antibodies were recycled. 
Samples were washed with 3 x 5 times PBS, followed by secondary antibody 
solution containing Alexa Fluor® (350/488/586/633) conjugate secondary antibody 
(Molecular Probes) (1:500 -1:1000 dilution) + 2% normal goat serum in PBS 
incubation at room temperature for 1h in the dark. Secondary antibodies were 
washed away with PBS, and slides were mounted with Prolong™ gold anti-fade 
mountant with or without DAPI (Molecular Probes). Regular epifluorescence imaging 
was done by Nikon Eclipse TE2000-U Fluorescent microscope. Confocal images 
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were captured with Leica LAS SP8 or Olympus FV-1200 confocal microscope 
(software FV10-ASW Version 4.3) with 60X Objective. All images were exported in 
TIFF format and analysis were done using Image J. 
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Table 2.2 Primary and secondary antibodies used in immunostaining 
Marker Primary 
antibody-
species and 
dilution 
Company and 
catalogue 
number  
Secondary 
antibody 
species 
and 
dilution 
Company and 
catalogue 
number  
α-synuclein 1:500 Mouse 
monoclonal, 
BD Biosciences, 
#610787 
1:1,000, 
Goat anti-
Mouse IgG 
(H+L) 
Highly 
Cross-
Adsorbed 
Secondary 
Antibody 
Life 
Technologies, 
Alexa Fluor  
#A11029 or 
#A11031 or 
#A11045 
Drp1  1:500 Mouse 
monoclonal, 
BD Biosciences, 
#611113 
1:1,000 
goat Goat 
anti-Mouse 
IgG (H+L) 
Highly 
Cross-
Adsorbed 
Secondary 
Antibody 
Life 
Technologies, 
Alexa Fluor 
#A11031 or 
#A21052 
α-synuclein 1: 2000  
Rabbit 
polyclonal , 
EMD Millipore 
(Millipore 
Sigma) 
#AB5038 
1:1,000 
Goat anti-
Rabbit IgG 
(H+L) 
Highly 
Cross-
Adsorbed 
Secondary 
Antibody 
Life 
Technologies, 
Alexa Fluor  
#A11034 
p62 1: 500  Rabbit 
polyclonal 
(SQSTM1) 
MBL 
International 
Corporation   
#PM045 
1:1,000 
Goat anti-
Rabbit IgG 
(H+L) 
Highly 
Cross-
Adsorbed 
Secondary 
Antibody 
Life 
Technologies, 
Alexa Fluor 
#A21071 
54 
 
 
 
Transmission electron microscopy (TEM) Cells used for TEM imaging were 
grown in tissue culture treated 6-well plates and treated with PonA. Upon harvesting, 
cell culture media was aspirated and cells were washed briefly with 2 ml of pre-
warmed wash buffer (0.1 M sodium cacodylate, 0.1 M sucrose, 3 mM CaCl2).Then 
wash buffer was replaced with 2ml pre-warmed fixative (2.5% glutaraldehyde in 0.1 
M sodium cacodylate, 0.1 M sucrose, 3 mM CaCl2), plates were incubated at RT for 
20min, followed by 4°C incubation for an additional 1h40min. Cells were then quickly 
rinsed with wash buffer, and scraped off of the culture surface into 1ml fresh wash 
HA 1:300  Mouse 
monoclonal 
(12CA5) 
 
Roche   
#11 583 816 
001 
1:500  Goat 
anti-Mouse 
IgG (H+L) 
Highly 
Cross-
Adsorbed 
Secondary 
Antibody 
Life 
Technologies, 
Alexa Fluor  
#A11045 
TOM20 1:1000 Rabbit 
polyclonal 
Santa Cruz  1:1,000 
Goat anti-
Rabbit IgG 
(H+L) 
Highly 
Cross-
Adsorbed 
Secondary 
Antibody 
Life 
Technologies, 
Alexa Fluor 
#A11011 
TH 1:1000 
Mouse 
monoclonal 
Sigma  
#T2928 
1:1,000, 
Goat anti-
Mouse IgG 
(H+L) 
Highly 
Cross-
Adsorbed 
Secondary 
Antibody 
Life 
Technologies, 
Alexa Fluor  
#A11029  
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buffer per well. Collected cells were then transferred into a 1.5ml Eppendorf protein 
low-bind tube centrifuged at 2000 x g for 5 min (note: It’s very important to use low-
bind tubes in order for fixed cells to pellet properly). Wash buffer was then replaced 
with 1 mL 1% osmium tetroxide in 0.1 M sodium cacodylate and incubated at RT for 
1 h. The pellet was then washed 2 x 10 min in 0.1 M sodium cacodylate and 1 x 10 
min in dH2O. After which cells were sequentially dehydrated in an increasing 
concentration of ethanol (30%, 50%, 70%, 90%, 3 x 100%) for 10 min each. Cells 
were then gradually infiltrated with increasing concentrations of resin (30%, 50%, 
70%, 2 x 100%), diluted in 100% ethanol, for at least 5 hours per concentration. 
    Samples were then polymerised within their original 1.5 mL tubes for 12 hours at 
60 °C.  Polymerised samples were then sectioned at 70 nm on ultra-microtome and 
subsequently stained with 0.5% uranyl acetate and 3% lead citrate. Processed 
samples were imaged with JEM-1400 TEM (From polymerisation every step was 
conducted at Plymouth University Electron Microscopy Centre, by Dr. Martin Helley 
and Jay Rees).  
 
Western Blot. Cultured cells were rinsed in PBS and then scraped off and collected 
in 1.5ml or 2ml Eppendorf tubes. The tubes were then centrifuged at 1000g for 3min, 
after which the supernatant was discarded, and pellets were either frozen down in -
80°C or processed immediately. For total cytosolic fraction, cell pellets were re-
suspended in RIPA buffer containing 1X Halt Protease and Phosphatase Inhibitor 
(Thermo Scientific), 75μl of buffer was used for a confluent T25. The suspension was 
then transferred to a 1ml glass homogeniser, dounced for 20 -30 times, and 
collected in 1.5ml Eppendorf tubes. The tubes were then centrifuged at 13,000rpm 
for 15 min at 4°C. Supernatants were collected for protein estimation using 
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bicinchoninic acid assay (BCA assay). Samples were mixed with 2X or 6X Laemini 
buffer, boiled at 98°C for 5-8min, and run through 12% or 15% Tris-bis gel (tris-
glysine system by Bio-rad), with 30-45ug of protein loaded into each well depending 
on the abundance of the target protein. Samples were then transferred to a PVDF 
membrane and probed with antibodies as listed in Table 2.3 below: 
 
Table 2.3 Primary and secondary antibodies and dilutions for western blot. 
Marker Primary 
antibody-
species and 
dilution  
Company 
and 
catalogue 
no. 
Secondary 
antibody 
Company Dilution 
 α-
synuclein 
Mouse 
monoclonal 
1:1000 
BD 610787 Goat anti-
mouse/ 
rabbit HRP 
conjugated 
secondary 
antibody 
Or 
IRDye 
800CW 
goat anti-
mouse 
/IRDye 
680RD goat 
anti-rabbit 
secondary 
antibody 
 
 
Bio-rad/ 
Li-COR 
1:10,000 
Drp1  Mouse 
monoclonal 
1:1000 
BD 611113 Bio-rad/ 
Li-COR 
1:10,000  
α-
synuclein 
Rabbit 
Polyclonal  
1: 2000 
EMD Millipore 
AB5038 
Bio-rad/ 
Li-COR 
1:10,000 
LC3B Rabbit 
Polyclonal 
1:1000 
Novus 
NB100-2220 
Bio-rad/ 
Li-COR 
1:10,000 
p62  Rabbit 
Polyclonal 
1:1000 
MBL   PM045 
(SQSTM1) 
Bio-rad/ 
Li-COR 
1:10,000 
β-Actin  Mouse 
monoclonal 
1:10,000 
Sigma   
A5441 
Bio-rad/ 
Li-COR 
1:15,000 
Tom 20 Rabbit 
Polyclonal 
1:4000 
Santa Cruz Bio-rad/ 
Li-COR 
1:10,000 
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    After HRP-conjugated secondary, blots were incubated in SuperSignal West Pico 
Chemiluminescent Substrate for 3 min. The blots were then exposed to X-ray films 
and developed in dark room. Films were scanned with Epson Perfection V800 
scanner and optical density of target bands were quantified using ImageJ. For 
fluorophore-conjugated secondary antibodies, blots were washed 3X with TBS and 
scanned with Li-Cor Odyssey Clx scanner and fluorescence intensity of target bands 
were quantified with Image Studio Ver 5.0.  
 
2.5 Functional analysis 
Mitochondrial membrane potential.  N27 α-syn cells were plated into 24-well 
plates and grown to approximately 85% confluency by the time of the assay. To 
measure mitochondrial membrane potential (ΔΨm), cells were trypsinised for single 
cell suspension and washed with warm phosphate buffered saline before being 
stained with 50nM tetramethylrhodamine methyl ester (TMRM) for 20 min at 37 °C. 
Fluorescent signal was analysed by BD Accuri C6 flow cytometer using FL-2 
channel. Cells were treated with 20 μM carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone for 20 min to collapse ΔΨm, and the obtained TMRM fluorescence 
was used to set the threshold. Data were expressed as the percentage of cells with 
signal above this threshold value as previously described (Cui et al., 2010a). Of note, 
TMRM was chosen for my study because it is one of the least problematic dyes for 
measuring ΔΨm due to its high selectivity and minimal effects on mitochondrial 
bioenergetics. It is less hydrophilic and more sensitive than R123, another commonly 
used tool for the same purpose.  
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Cellular Oxidative stress. Dihydroethidium (DHE, Invitrogen) was applied to 
measure oxidative stress by quantifying reactive oxygen species (ROS) in cells. 
Cells were grown in 24-well plates and treated accordingly. Upon assay, 10µM DHE 
were added to cell culture media, incubated for 20 min at 37°C, 30mM H2O2 was 
used as a positive control. The dye was then washed away with PBS, and cells were 
detached by tryspin, re-suspended in PBS+2%FBS, and analysed by flow cytometry. 
Data were expressed as the percentage of cells with signal above threshold set by 
H2O2. 
 
Mitochondrial oxidative stress. To identify the source of ROS, mitochondrial 
oxidative stress was assessed using MitoSOX red (M36008, Molecular probes). 
Cells were plated in 96-well plate (for plate-reading) and coverglass in 24-well plate 
(for imaging), treated with PonA and different fission/fusion modulators. 48h of 
Rotenone (50mM) treatment was used as a positive control for mitochondrial ROS. 
    Upon assay, cells were washed two times with warm HBSS, followed by 2.5 µM of 
MitoSox working solution (in HBSS) incubated at 37C for 20min. Cells were then 
washed 2X with PBS to remove MitoSOX residue, and fixed with 4%PFA. (20min at 
37°C). 
    For plate-reading, cells were washed with PBS 3X times and the fluorescence was 
measured using Spec at Ex/Em 510/595. After which cells were washed with 2X 
PBS, incubated with DAPI (5ug/ml) in dark at room temperature for 10 min. 3X PBS 
washes were repeated to wash away excessive DAPI, and DAPI signal was also 
quantified through plate reading (Ex/Em 358/461). 
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 Mitochondrial Respiration.  Mitochondrial function in live cells was assessed using 
a Seahorse XFe 96 Analyser (Seahorse biosciences Inc). Cells were grown in XFe 
96 tissue culture plate, 
and standard Mito 
Stress test (Figure 2.2) 
were carried out for 
real-time assessment of 
mitochondria function. 
Briefly, on the day of 
experiment, cell culture 
media was replaced 
with 175ul serum free 
assay medium 
(Dulbecco’s Modified 
Eagle’s Medium with - 
5.5mM Glucose, 1.0mM 
Sodium Pyruvate, 4mM 
Glutamine, 2mM 
HEPES, pH 
7.4),.incubated in a 
37°C non-CO2 incubator 
for at least 30min before being loaded into the analyser. Mitochondrial respiration 
was measured using the Mito-Stress Test (Seahorse Biosciences Inc) as instructed 
by the manufacturer. Oligomycin (1μg/ml), FCCP (0.5μM), rotenone (1μM) and 
Figure 2.2 Mito Stress Test kinetic profile with assay 
parameters. The standard Mito Stress test consists of 
three sequential injections of Oligomycin (ATP synthase 
inhibition), FCCP (remove proton restriction, stimulating 
maximal respiration) and Rotenone& antimycin-A 
(shutdown ETC).  non-Mitochondrial Respiration is the 
minimum rate after Rotenone/antimycin-A injection. Basal 
Respiration=(Last measurement before Oligomycin 
injection) – (non-Mitochondrial Respiration).  Maximal 
Respiration = (Maximum rate after FCCP injection) - 
(non-Mitochondrial Respiration).  Spare Respiratory 
Capacity%= (Maximal Respiration) / (Basal Respiration) 
× 100. Coupling Efficiency ATP Production Rate) / (Basal 
Respiration Rate) × 100. (Permission to reproduce this 
image has been granted by Agilent Technologies, Inc.)
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antimycin A (1μM) were sequentially added to cells to determine mitochondrial 
respiration. Each oxygen consumption rate data point refers to the mean rates during 
each measurement cycle, which consisted of a mixing time of 30 s followed by a 
data acquisition period of 3 min. Three data points were acquired after each 
injection, and four data points were recorded for basal respiration.  For 
normalization, cells were fixed with 4% PFA, followed by incubation of DAPI (80μl of 
5μg/ml in PBS) for 10 min. The plate was then washed 3 time with PBS, and 
fluorescent signal DAPI for was quantified at Ex/Em 358/461 nm using the Biotak 
Synergy H1 Hybrid Reader. 
 
Autophagic vesicles analysis. The analysis of autophagy flux in HeLa cells was 
performed in a similar way as described by (Button et al., 2014) Green vesicles are 
considered to be autophagosomes, as when the autophagosome fuses with the 
lysosome, the pH sensitive GFP signal is quenched by the acidic environment. Red 
vesicles are made up of both autophagosomes and autolysosomes. The number of 
autolysosomes was achieved by subtracting the number of green vesicles from that 
of the red vesicles. For analysis, cells were imaged with an Olympus Fluoview with 
60x time objective, autophagosomes and autolysosomes from at least 50 cells per 
treatment group were counted using ImageJ. 
    For N27 cells, autophagy blockage was assessed either through western blot 
analysis of LC3-II (autophagic membrane protein) and p62 (autophagy substrate) 
level, or through quantification of LC3-cherry puncta together with p62 puncta 
through immunostaining. 
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2.6 Protein aggregation 
Proteinase K digestion for immunocytochemistry (ICC). To determine the 
formation of aggregation in cells, Proteinase K (PK) digestion was performed.  For 
ICC plates used for PK digestion, freshly fixed cells were washed 3 X 5min with 
PBS, then treated with PK solution (~0.34U/ml, Sigma P4850) diluted in PBS. The 
plates were then be incubated in the dark at room temperature for 10min with gentle 
shaking, followed by 3 X 5min washes with PBS. After washing the plates were 
ready to proceed to blocking and subsequent ICC staining for α-syn. 
 
Pre-formed fibrils (PFF) treatment. α-syn monomers were obtained from the 
Michael J. FOX Foundation, and the generation of PFF was performed according to 
manufacturer’s protocol: The frozen aliquot was thawed on ice, spun at 15,000g for 
10 min at 4°C with a SORVALL legend micro 21R centrifuge (Thermo Scientific). 
BCA was then performed to determine the concentration (triplicates at 3 different 
dilutions), and protein sample was diluted in sterile dPBS (gibco 14190-144) to 
5mg/ml in a 1.5ml Eppendorf protein low-bind tube. The sample was quickly votexed 
and placed in an Eppendorf ThermoMixer C orbital shaker (with thermo top on), 
shaken at 1,000 RPM for seven consecutive days at 37°C. Sample was then divided 
into 25μL aliquots and stored at -80°C. 
Upon use, an aliquot was thawed at room temperature, diluted into 0.1mg/mL 
using sterile dPBS (volume 200-400µL), and sonicated with a Fisher Scientific 120 
Sonic Dismembrator with CL-18 microtip (30 X1s pulses, 20% power). Sonicated 
solution was immediately added to Hela cells grown in 6-well plates (10μg/well). 
Cells were incubated with PFF for 48h, and PFF media was placed with fresh culture 
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media, and cells were further incubated for 24h before fixation for immunostaining. 
TEM images were captured by collaborators in Fudan University, China. 
 
2.7 synaptosome isolation and functional analysis   
Synaptosome isolation in rats  Synaptosomes were isolated from Sprague Dawley 
adult rats based on a previous publication(Choi et al., 2009b) but with some 
modifications. Briefly, striata were quickly removed, rinsed with ice-cold sucrose buffer 
(320 mM sucrose, 1 mM EDTA, 0.25 mM dithiothreitol, pH 7.4).and then homogenized 
(10-12 strokes) in dounce glass homogenizer containing 1-1.5 mL sucrose buffer. The 
homogenates were transferred to 2ml Eppendorf tubes, spun at 1000g at 4°C for 
10min. The supernatants were collected and then gently layered onto a discontinuous 
Percoll gradient (2.5ml of 3%, 10% and 23% in sucrose buffer) in 10 mL centrifuge 
tubes, and centrifuged at 32500 g for 10 min at 4°C in a JA-25.50 fixed angle rotor in 
a Beckman Avanti J-26 X centrifuge. The band between 10% and 23% from striatum 
was collected for synaptosomes, pelleted and resuspended in ionic buffer (20 mM 
HEPES, 10 mM D-glucose, 1.2 mM Na2HPO4, 1 mM MgCl2, 5 mM), protein 
concentration was measured using nano drop 2000.  
 
Mitochondrial function in striatal synaptosomes. Isolated striatal synaptosomes 
(2ug/well) were plated into an XFe96 cell culture microplate (Seahorse Bioscience Inc.) 
which was previously sequentially pre-coated with 0.0033% (v/v) polyethyleneimine 
(Sigma-Aldrich) and Geltrex (Invitrogen). The plate was centrifuged at 3400g for 1h at 
4 ºC in a Henttich Rotanta 460R centrifuge to facilitate attachment. The ionic buffer 
was then replaced with 175µL assay buffer (3.5 mM KCl, 120 mM NaCl, 1.3 mM CaCl2, 
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0.4 mM KH2PO4,1.2 mM Na2SO4, 15 mM D-glucose, 10 mM pyruvate, 0.4% (w/v) 
fatty acid-free bovine serum albumin, and 10 mM TES (N-[tris(hydroxymethyl)methyl]-
2-aminoethanesulfonic acid), pH 7.4). The plate was incubated in a non-CO2 incubator 
at 37ºC for 10-15min, then loaded into the XFe96 Extracellular Flux Analyzer 
(Seahorse Biosciences Inc.)  Mitochondrial function in these synaptosomes, as 
indicated by oxygen consumption rate (OCR), was monitored in real-time throughout 
the assay. Different parameters of mitochondrial respiration were obtained with 
sequential injections of 2.5 μg/ml oligomycin, 4 μM FCCP and 2 μM 
Rotenone/Antimycin. Oxygen consumption rate data points represents the mean rates 
of each measurement cycle, which consisted of 30 s mixing time,30s waiting time, 
followed by 3 min of data acquisition. Basal respiration was measured before the first 
injection (3 cycles), and 3 data points were obtained following each injection (12 data 
points in total). 
 
2.8 Statistical Analysis  
Data represent the mean ± SEM. For all in vitro experiments with two groups, 
student t-test was applied as they all pass normality test. For normally distributed 
data with more than 2 groups, differences between means were analysed using one-
way ANOVA, followed by Newman-Keuls post hoc testing for pairwise comparison. 
The Newman-Keuls was post hoc analysis method was selected for its intermediate 
stringency and it’s not too conservative. For in vivo study and for in vitro experiment 
with 2 variables, Statistical analysis was performed using two-way ANOVA, followed 
by Tukey multiple comparison test. All statistical analyses were performed by 
SigmaStat 3.5 software. The null hypothesis was rejected when the p value < 0.05. 
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3. Inducible α-syn overexpression in 
N27 cells impairs mitochondrial 
morphology and function by 
enhancing fission
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3.1. Introduction 
As discussed in Section 1.3, -syn has been demonstrated to induce neurotoxicity 
through multiple but non-mutually exclusive mechanisms (Bourdenx et al., 2015b, 
Dehay et al., 2015a, Franco-Iborra et al., 2016, Helley et al., 2017a), including 
impairment in mitochondrial and autophagy-lysosomal function – two mechanisms 
that are relevant to my research. α-syn has been reported to induce mitochondrial 
dysfunction and fragmentation in experimental models of PD (Chen et al., 2015, 
Winslow and Rubinsztein, 2011, Kamp et al., 2010, Gui et al., 2012). However, 
whether α-syn impairs mitochondrial function and morphology through imbalanced 
mitochondrial fission and fusion ratio is still a topic of debate (as discussed in 
Chapter 1, section1.3.4.3). This is one of the main questions that I would like to 
address in my study. 
   To address this issue, I started with a dopaminergic neuronal cell model with 
inducible human wild-type α-syn expression. The major advantages of a stable 
inducible cell line comparing to transient transfection and non-inducible stable cell 
line include: 
1. More homogeneous population compared to transient transfection, and 
therefore results would be more consistent and reproducible. 
2. For proteins that could be toxic such as α-syn, a stable cell line with 
continuous overexpression of the protein would potentially act as a selective 
factor that would change the properties of the surviving cells. An inducible cell 
line tackles the problem by controlling the timing and duration of the protein 
expression. 
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3. With controlled level and time of protein expression, inducible cell line offers 
the flexibility to assess the impact of α-syn in a time depend manner and 
establish the preferred overexpression level via controlling PonA dose and 
time.  
    In addition, the flexibility of cultured cell line, comparing to primary culture, allows 
me to test different genetic approaches to confirm the effect of certain proteins. This 
is vital for establishing a model targeting certain pathways as small molecule 
approaches alone does not offer enough specificity. iPSC cells were also considered 
as an alternative, however, the problem with heterogeneous genetic background at 
the time became a major concern and this was put on hold. Another immortalised 
dopaminergic cell line, LUHMES, was also considered for generating the stable cell 
line. LUHMES have been established to be differentiated morphologically and 
functionally mimicking primary dopaminergic neurons (Scholz et al., 2011, 
Schildknecht et al., 2013). Due to technical issues as discussed later in this chapter, 
I was unable to generate inducible stable LUHMES cells. 
My two initial objectives were to first test the effects of α-syn overexpression on 
mitochondrial morphology and function. Second, determine whether blocking Drp1 
would attenuate the negative impacts of α-syn on mitochondria. 
 
3.2. Materials and Methods 
3.2.1. Cell culture, differentiation and α-syn induction 
Two dopaminergic neuronal cell lines have been used in this Chapter, the stable N27 
cells and LUHMES cells. Most studies were done with stable N27 cells due to the 
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difficulties of generating stable cell line or transient transfection I encountered with 
LUHMES cells (discussed in section 3.3). 
Stable N27 cell culture and differentiation To investigate the impact of α-syn 
overexpression on mitochondria in detail, an inducible cell line was generated by 
stably transfecting rat dopaminergic neurons (N27) with an ecdysone system 
containing human SNCA gene (see Chapter 2 Fig. 2.1). Population of cells with 
inducible α-syn expression were sorted using an mRNA probe specific to human α-
syn (Fig. 3.1A). Cells were maintained in selective media containing RPMI +10% 
FBS+G418+ Hygromycin B. In the beginning of the study, attempts were made to 
explore the potential of using differentiated N27 cells with more dopaminergic 
properties. Different concentrations of Dibutyryl cyclic-AMP (dbcAMP, Sigma) and/or 
DHEA (sigma) were tested out as indicated in Fig. 3.2. 
α-syn induction To induce α-syn induction, different doses (up to 30 µM) of 
Ponasterone A (PonA, Enzo, ALX-370-014-M005, 2mM stock in Ethanol) were 
diluted into cell culture media right before treatment. 10 and 20µM were established 
as most effective doses and used for subsequent tests. Cells were incubated for 24, 
48 and 72h for respective tests. 
LUHMES cell culture and differentiation. Lund human mesencephalic LUHMES 
cell line (ATCC® CRL-2927™) were maintained in complete growth media 
containing DMEM/F-12 +1% N-2 supplement (Gibco-Invitrogen 17502-048) + 40 
ng/ml b-FGF (basic recombinant human Fibroblast Growth Factor; Gibco-Invitrogen 
13256-029), with b-FGF always added fresh right before use. All cell culture surfaces 
were sequentially pre-coated with 50 µg/mL poly-L-ornithine at room temperature 
overnight (Sigma, P-3655), and then with 1 µg/mL Human Fibronectin (Sigma, F-
0895) at 37°C for 3 hours. For differentiation, bFGF in complete growth medium 
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were replaced with tetracycline (1μg/ml, diluted 1:1000 from 1mg/ml stock), GDNF 
(glial cell line-derived neurotrophic factor, 2ng/ml, diluted 1:1000 from 2μg/ml stock), 
and db-cAMP (1mM, diluted 1:100 from 100mM stock). Cells were differentiated up 
to 10 days and were plated for experiment at Day 2 of differentiation to control the 
cell number. 
 
3.2.2. Immunoassays and qPCR 
Immunocytochemistry. To confirm and characterise the expression of α-syn, 
antibodies against α-syn (mouse monoclonal antibody  BD 610787) (1:500) and 
rabbit polyclonal antibody AB5038 (1:2000) were used for immunocytochemistry ). 
For autophagy assessment, antibody against p62 (rabbit polyclonal, MBL PM045) 
was used at 1:500 dilution. For cell differentiation characterisation, antibodies 
against TH (mouse monoclonal, Sigma T2928, 1:500 dilution) and Tom 20 (rabbit 
polyclonal, Santa Cruz sc-17764 ,1:1000 dilution) were used. (more details in 
Chapter 2, Table 2.2) 
Western blotting. Upon experiments, cell pellets were collected and lysed with 
RIPA buffer with proteinase inhibitors, homogenised on ice, and supernatants were 
loaded on to a 12% SDS-PAGE for separation and transferred to a PVDF 
membrane. After blocking with 2.5% skin milk, membranes were incubated in 
primary antibody solutions at 4C overnight: anti-a-syn (1:1000, BD 610787), anti-
Drp1 (1:2000, BD 61113), anti-β-actin (1:10,000, Sigma A2228). more details in 
Chapter 2, Table 2.3) 
qPCR. Cells were harvested after 24, 48 and 72hrs after PonA induction. mRNA was 
extracted using RNeasy Mini Kit (Qiagen) followingmanufacturer’s instructions. The 
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isolated mRNA concertation was measured by NanoDrop™ 2000 
Spectrophotometer, and cDNA were generated using Thermo Scientific RevertAid 
First Strand cDNA Synthesis Kit. 1µl of cDNA were mixed 1µl of each primer and 
with Roche LightCycler® 480 SYBR Green I Master. qPCRs were run in 
LightCycler® 480 Instrument using a 384-well plate with 10 µl reaction volume.  
 
3.2.3. Functional Studies 
Mitochondrial membrane potential. Stable N27 cells were treated with PonA for 
48h with or without Drp1 inhibition. They were then stained with 50nM 
tetramethylrhodamine methyl ester (TMRM) for 20 min at 37 °C. Fluorescent signal 
was analysed by BD Accuri C6 flow cytometer using FL-2 channel. For positive 
control, cells were treated with 20 μM (FCCP for 20 min to collapse ΔΨm, and the 
obtained TMRM fluorescence was used to set the threshold. FCCP uncouples the 
proton current with ATP production, taking away limitation of proton flow(Singleton et 
al., 2003b), as a result mitochondria membrane no longer have the ΔΨm generated 
by ETC complex.    
Oxidative Stress (cellular). Stable N27 cells were treated with PonA for 48h 
with/without Drp1 inhibition. Upon assay, 10µM Dihydroethidium (DHE) were added 
to cell culture media, incubated for 20 min at 37°C, 30mM H2O2 was used as a 
positive control. DHE gets oxidized by superoxide to form ethidum or 2-
hydroxyethidium (ex 500-530 nm/em 590-620 nm)(Owusu-Ansah et al., 2008), and 
the change in red fluorescence can be quantified as indicators for oxidative stress. 
The dye was then washed away with PBS, and cells were detached by tryspin, re-
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suspended in PBS+2%FBS, and analysed by flow cytometry. Data were expressed 
as the percentage of cells with signal above threshold set by H2O2. 
Mitochondrial oxidative stress .To identify the source of ROS in stable N27 cells, 
mitochondrial oxidative stress was assessed using by 2.5 µM MitoSOX red (M36008, 
Molecular probes). Cells were plated in 96-well plate (for plate-reading), treated with 
PonA and different fission/fusion modulators for 48h. Rotenone (50mM) treatment for 
48h was used as a positive control for mitochondrial ROS because Rotenone 
induces mitochondrial ROS by directly and selectively blocking mitochondrial 
complex I(Palmer et al., 1968). Plate reading (Ex/Em 510/595) was done to quantify 
mitochondrial ROS. Normalisation was done using DAPI (Ex/Em 358/461).  
Mitochondrial respiration. N27 stable cells were grown in XFe 96 tissue culture 
plate and treated with PonA for 24h. On the day of experiment, cell culture media 
was replaced with 175ul XF assay medium (Dulbecco’s Modified Eagle’s Medium 
with 4.5mM Glucose, sodium pyruvate, PH7.4), incubated in a 37°C non-CO2 
incubator for at least 30min before being loaded into the analyser. Mitochondrial 
respiration was measured using the Mito-Stress Test (see Chapter 2, Figure 2.2) 
(Seahorse Biosciences Inc) as instructed by the manufacturer. Oligomycin (1μg/ml), 
FCCP (0.5μM), rotenone (1μM) and antimycin A (1μM) were sequentially added to 
cells to determine mitochondrial respiration. For normalization, cells were fixed with 
4% PFA, followed by incubation of DAPI (80μl of 5μg/ml in PBS) for 10 min. The 
plate was then washed 3 time with PBS, and fluorescent signal DAPI for was 
quantified at Ex/Em 358/461 nm using the Biotak Synergy H1 Hybrid Reader. 
Autophagy and protein aggregation assessment. To assess autophagy, N27 
cells were transfected with LC3-cherry, a marker for autophagosomes and 
autolysosome membranes. And an autophagy substrate, p62 was also marked for 
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quantification. To quantify aggregation in immunostained cells, slides were incubated 
with 0.34U/ml Proteinase K (PK) solution (in PBS) for 10min at RT before proceeding 
to blocking. PK is a nonspecific  serine protease that degrades many proteins in the 
native state(Ebeling et al., 1974), and aggregated forms of proteins will survive the 
digestion. All puncta quantifications were achieved using image J. (see section 2.7 
for more details) 
 
3.2.4. Cell viability assays 
MTT cell viability assay. Cells were plated in 96-well plates (5,000/well for 72h). On 
the day of assay, 25μl of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide) was added into each well, incubated in the dark at 37°C for 3 hours, 
followed by the addition of 100μl of MTT lysis buffer. The plate was then left 
overnight for the crystals to dissolve. Plate reading was done the following day after 
confirming that all the crystals were dissolved, and optical density at 562nm was 
measured using a Genois one plate reader. 
Calcein AM cell viability assay. Calcein, AM (Invitrogen,1mg/ml in DMSO) was 
purchased from Thermo Fisher Scientific. Working solution (2µg/ml) was made up in 
PBS each time prior to experiment. N27 cells were grown in flat bottom 96-well 
plates and induced with PonA for 72h with/without Drp1 inhibition. Upon assay, cells 
were washed with warm dPBS by replacing half the volume of media with dPBS and 
leave 50µl PBS in each well.100µl Calcein solution was then added to each well and 
the plate was incubated in dark at room temperature for 1 h. Fluorescence signal 
was quantified using Synergy H1 Hybrid Reader (Ex/Em 494/520).     
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3.2.5. Imaging 
Regular fluorescence imaging was done by Nikon Eclipse TE2000-U Fluorescent 
microscope. Confocal images were taken by Olympus FV1000 with X60 Objective. 
For TEM imaging, cell samples were processed and imaged with JEM-1400 TEM 
(imaging were conducted at Plymouth University Electron Microscopy Centre, by Dr. 
Martin Helley and Jay Rees). 
 
3.3. Results 
To assess the inducible expression of α-syn in the stable N27 cells, I performed a 
pilot study by treating cells containing SNCA or empty vector control with varying 
concentrations of PonA for 48h to induce α-syn expression. Immunostaining (Fig 
3.1) shows that at 5 µM, the expression of α-syn was minimal, but at 10 µM and 
higher concentrations, immunofluorescent signal of α-syn was high. In contrast, the 
group of cells with empty vector control treated with 20 µM did not produce a 
detectable expression. 
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Figure 3.1 Dose-response study of α-syn in stable N27. Cells were grown on 
coverslip glass, induced with differing doses of PonA (5-30 µM) for 48h before 
fixation and immunostained for α-syn. Images were captured using Nikon 
ECLIPSE TE2000-U fluorescent microscope with 60X objective. Scale bar: 30µm. 
 
  Next, to select stable cells with high expression of α-syn, cells with SNCA or empty 
vector control cells were treated with PonA (20µM) for 24h to induce α-syn 
expression. Cells were then sorted using FACS with an mRNA probe specific to 
human SNCA (Fig. 3.2A), the uptake of probe was confirmed by imaging, as shown 
in the left panel, the probe (red dots) distribution were much higher in some cells.  
And when quantified by FACS, there was a clear shift to the right (higher fluorescent 
signal) in the distribution curve after induction. Cell populations in both P1 (lower 
levels) and P2 (higher levels) gates of induced cells were collected.   
    Cells with high SNCA levels were selected and the inducible expression of α-syn 
was then further characterised by performing dose-response and time-course 
studies of PonA treatment. Based on the results obtained from qPCR (Fig. 3.2B) and 
western blotting (Fig. 3.2C&D), robust α-syn overexpression was induced as early 
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as 24 after PonA treatment. Immunoblotting data show PonA at 20 µM for 48h as the 
most optimal regimen to induce α-syn expression based on protein level; therefore, 
for subsequent studies, cell were treated with these experimental conditions - unless 
otherwise specified. Although I could not completely control the exact level of α-syn 
overexpression by different dose of PonA, the inducible cell line still offers a lot of 
flexibility and control regarding the time and relative lower levels of expression 
compared to stable non-inducible cell line and transient transfection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
 
 
Figure 3.2 Purification and characterisation of stable cells with inducible α-
syn.  (A) Rat dopaminergic neuronal N27 cells transfected with ecdysone-
inducible system containing human α-syn were induced with PonA (20µM) for 
24h, and then incubated with SMARTFlare Cy3-hα-syn mRNA probe overnight 
before analysis. Left panel: The uptake of probes was confirmed by confocal 
imaging using Cy-3 signal (PE Ex/Em 496/578) combined with phase contrast. 
Right panel: Cell sorting by FACS, Cy-3 signal shift with PonA induction. Two 
populations (P1 & P2) of cells with α-syn expression levels were collected. P1 
(higher expression) population was used for further experiments.  (B) qPCR 
analysis of α-syn expression over different time points. Data presents Mean ± 
SEM, n=3. p*<0.05 against empty vehicle control. (C&D) Concentrations of 10, 20 
and 30 µM of PonA were tested at different time points (24h, 48h & 72h) to 
determine the optimal conditions for α-syn expression. Western blot analysis of α-
syn overexpression in a time and dose dependent manner. Each PonA dose was 
compared to its respective control using One-way Anova. Data presents Mean ± 
SEM, n=4. p*<0.05 against empty vehicle control. 
   
    In an attempt to improve the cell culture model to make it more neuronal like, I 
tried differentiating N27cells (Figure 3.3) adapting a protocol previously 
described(Prasad et al., 1994, Adams et al., 1996) .using Dehydroepiandrosterone 
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(DHEA) and dibutyryl cyclic AMP (dbCAMP). I tested two concentrations of DHEA 
and three concentrations of dbCAMP. At day 2, dbCAMP 0.5mg/ml long neurites in 
these cells were observed at both concentrations of DHEA, suggesting cells started 
to differentiate. Although this was encouraging, these differentiated cells started to 
die after day 3. After a few attempts, this low cell viability prevented me from using 
this cell model for my work.   
 
 
Fig 3.3. N27 differentiation characterisation at different concentrations of 
DHEA and dbcAMP. Stable N27 cells were grown on glass coverslips coated with 
poly-D-lysine. Cells were differentiated for up to 4 days with DHEA + dbcAMP. 
Different ratios of the two compounds (as indicated) were tested and morphology 
change was tracked every day with a Leica phase contrast microscope. 
Representative images were shown. Scale bar: 50µm.  
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    To complement the N27 cells, which are rat dopaminergic neurons cells, I tried to 
set up a second model using LUHMES cells, which represent a human 
mesencephalic-derived cell line (Schildknecht et al., 2013) Based on the cell 
differentiation protocol of that publication, I differentiated these cells for 10 days and 
immunostained for tyrosine hydroxylate (TH), a marker commonly used for 
dopaminergic neurons. As shown in Figure 3.4A, the expression of TH was 
noticeable after day 5 of differentiation. Next, I assessed the response of LUHMES 
cells to a neurotoxin. As compared to N27 cells, even without differentiation, 
LUHMES cells showed higher sensitivity to paraquat (Figure 3.3B), a pesticide 
widely used in PD-related studies (Cicchetti et al., 2005, Thiruchelvam et al., 2000). 
Together, these two observations led me to believe that I could use LUHMES cells to 
generate a human dopaminergic cell model with inducible α-syn. However, when I 
started to use these cells to generate an inducible model , I encountered two 
problems:  
1. Low transfection efficiency. Common lipid-based methods like lipofectamine and 
other chemical transfections resulted in very little transfected cells, electroporation 
did give higher transfection efficiency, but the aggressive nature of the method 
resulted in much lower cell viability. According to literature, the common method of 
LUHMES cell transfection is through lentivirus (Krug et al., 2014), which was not 
feasible for me to perform at the time. 
2. Compatibility with the inducible construct: To generate a stable inducible cell line 
using the same constructs that I had for the generation of the N27 stable cells, the 
cells would go through two selection processes with G418 (neomycin) and 
Hygromycin B. Generated from MESC2.10, LUHMES cells already contains 
neomycin-resistant gene, which would lead to unsuccessful selection with current 
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scheme. An alternative construct needs to be designed if I were to generate stable 
inducible cell line in the future. Given that I had already generated stable N27 cells, I 
decided to use those stable cells for my study. 
 
 
Fig 3.4. LUHMES cell characterisation. (A). Differentiation shows increased TH 
expression over time. LUHMES cells were grown on coverslip glass pre-coated 
with poly-L-orthine and fibronectin. Complete growth media was replaced with 
differentiation medium containing DMEM/F12 + N-2 +Tetracycline + dbcAMP + 
bFGF, cells were differentiated up to 10 days and fixed at different dates as shown 
above. (B). Cells grown in 96-well plates were treated with different doses of PQ 
(as indicated) for 24 and 48h, and 25 µl MTT (5 mg/mL in PBS) were added 
directly to the wells containing 100 µl media. Optical density was determined by 
measuring absorbance at end point 560. Data represent the mean ± SEM, n=3-5 
independent experiments. Statistical analysis for was performed using two-way 
ANOVA ***p<0.001) 
 
80 
 
 
3.3.1. α-syn overexpression induces mitochondrial fragmentation and 
Drp1 translocation to mitochondria 
With the inducible dopaminergic N27 cells characterised, I assessed the impact of 
α-syn on mitochondrial morphology. Cells were transfected with DsRed-Mito to 
label mitochondria with a red-fluorescent signal. This approach avoids the 
problems of mitochondrial dyes such as specificity and signal intensity being 
affected by mitochondrial membrane potential. Cells were then induced with PonA 
for α-syn overexpression, which as shown in Fig3.5A, induced mitochondrial 
fragmentation with a peri-nuclei distribution after 48h. However, stable cells with 
empty vector control displayed tubular mitochondria. The observed mitochondrial 
fragmentation appeared to be mediated by Drp1 because increased levels of this 
fission protein were observed at the mitochondrial and total levels, as 
demonstrated using immunohistochemistry (Fig3.5A) and immunoblotting 
(Fig3.5B), respectively. Mitochondrial morphology was further quantified using 
ImageJ and expressed as Roundness and Aspect Ratio (Fig 3.5C & D). Both the 
values of “roundness” and “aspect ratio” approach 1 as the particle becomes 
circular. 
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Fig3.5 α-syn overexpression induces mitochondrial fragmentation. 
(A) Stable N27 cells with α-syn or empty vector control were transiently
transfected with the mitochondria label Ds-Red-mito and then induced with
PonA for 48h. Cells were fixed, stained and imaged using confocal
microscopy. Antibodies against Drp1 and α-syn were used to label the two
proteins. Scale bar: 20µm. (B) Stable N27 cells were induced with PonA
for 48h, and then harvested, lysed with RIPA buffer and separated with
SDS-PAGE. Blots were probed as indicated using antibodies as indicated.
Data represent the mean ± S.E, n=4 per group, student t-test * p<0.05. (C
and D) Quantification of mitochondrial perimeter by ImageJ using ICC
images captured with confocal. Data represent the mean ± SEM, n=4 with
approximately 50 cells counted per group per experiment, student t-test *
p<0.05. Roundness = 4X[Area] / (πX [Major axis]2). Aspect Ratio = [major
Axis]/ [Minor Axis].
82 
 
 
3.3.2.  α-syn overexpression impairs mitochondrial function and 
reduces cell viability 
Based on the observation that inducible α-syn impaired mitochondrial morphology, I 
asked whether mitochondrial function was also impaired in this cell model. Known as 
the ‘powerhouse’ of the cell, ATP generation through oxidative phosphorylation is the 
predominant physiological function of mitochondria. Abnormality in any of the 
processes that impair oxidative phosphorylation function can cause mitochondrial 
dysfunction. In this project, I used complementary approaches to evaluate 
mitochondrial function:  
    First, I measured mitochondrial membrane potential (ΔΨm), which is established 
by the electrochemical gradient from redox reactions generated by the mitochondrial 
electron transport chain (ETC). This gradient is responsible for driving ATP 
production, and therefore a decrease in ΔΨm is indicative of unhealthy mitochondria. 
As shown in Fig. 3.6A, after 48h of induction, α-syn significantly reduced ΔΨm to 
approximately 50% of the control group without α-syn expression. 
    Second, oxidative stress is generated from overproduction of free radicals such as 
reactive oxygen species (ROS). ROS could lead to mtDNA mutations, protein 
aggregation and have been implicated in cell death and ageing. An impairment in 
mitochondrial function invariably would lead to free radical production such as ROS. 
To determine whether such ROS production would originate from mitochondria 
resulting in a higher total cellular ROS, I quantified MitoSOX Red and 
Dihydroethidium (DHE) signals to detect mitochondrial superoxide and cellular ROS 
levels, respectively. Rotenone, a complex I inhibitor, was used as a positive control 
to generate ROS from the ETC blockade. Consistent with its inhibitory effect on 
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mitochondrial function, α-syn increased ~30% mitochondrial and 400% cellular ROS 
levels (Fig 3.6B-C).  
    Third, to measure mitochondrial function more directly and to gain more insights 
into the kinetics of mitochondria respiration impaired by α-syn, I quantified 
mitochondrial oxygen consumption using the Seahorse XFe96 Extracellular Flux 
Analyzer. Fig 3.7 shows that α-syn specifically reduced mitochondrial spare 
respiratory capacity (SRC), which represents the ability of mitochondria to provide 
substrate supply and electron transport in response to an increase in energy 
demand.  
    The three parameters above were chosen because each of them provides a 
different but complementary aspect of mitochondrial health. The simultaneous drop 
in ΔΨm, spare respiratory capacity and increase in ROS consistently indicates 
mitochondrial dysfunction. Taken together, these three mitochondrial studies support 
the negative effects of α-syn on the mitochondrial function.  
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Fig3.6 α-syn overexpression collapses ΔΨm, increases both cytosolic and 
mitochondrial ROS. (A) Stable N27 cells with α-syn or empty vector control were 
incubated for 20min at 37°C with 50nM TMRM, and 20μM uncoupler FCCP were 
added as positive control to collapse membrane potential, a value that served as a 
threshold for subsequent quantification. Cells were run through a flow cytometer 
and ΔΨm signal was recorded. Data are expressed as % above threshold, arbitrary 
units (AU). (B) Cellular ROS was measured by incubation with 10 μM DHE for 
20min at 37°C and analysed by flow cytometry. Data expressed as % above 
threshold. (C) MitoSox red signal was measured by incubation cells with 2.5 μM 
working solution of the dye for 20 min and analysed by fluorescent plate reader 
(Ex/Em 510/580nm). For normalization, cells were fixed and subsequently stained 
with DAPI (Ex/Em 385/461 nm) for cell density, and relative fluorescence units 
(RFU) were calculated by dividing mitosox intensity against DAPI. Rotenone was 
used as a positive control because it produces ROS by blocking mitochondrial 
function. Data represents Mean ±SEM, n=4 independent experiments, student t-
test. *p<0.05. 
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Fig 3.7 α-syn overexpression reduces mitochondrial spare respiratory 
capacity. (A)  Kinetic illustration of mito-stress assay. Three sequential injections 
of Oligomycin (to inhibit oxygen consumption mediated by ATP synthase), FCCP 
(an uncoupler to induce maximal OCR), and Rotenone/Antimycin (to inhibit 
complex I and III, respectively) were done after basal respiration measurement (B) 
Stable N27 cells with α-syn or empty vector control were grown in Seahorse XF96 
Cell Culture Microplates were analysed by a Seahorse XFe96 Analyzer. α-syn 
overexpression impaired spare respiratory capacity% (=Maximal Respiration/ 
Basal Respiration). Data represents Mean ± SEM, n=4 independent experiments, 
student t-test. *p<0.05. 
 
   As mitochondrial spare respiratory capacity determines the capability of producing 
extra energy on demand, it serves as an important indicator for cell survival under 
stressed conditions. Therefore, cell viability assays were conducted. Although at 24h 
and 48h (data not shown) no change in cell number was observed, at 72h there was 
a clear reduction in cell viability as quantified by using MTT (Fig 3.8A) and Calcein 
assay (Fig 3.8B). MTT assesses cell metabolic activity as it’s reduced to formazan 
by mitochondrial succinate dehydrogenase. Calcein AM is a non-fluorescent cell-
permeant dye that can be converted to green-fluorescent calcein in live cells. The 
green fluorescence was quantified using a plate reader. Together, these two cell 
viability assays indicate that cell density is slowly reduced over time when α-syn is 
over-expressed. 
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Figure 3.8 α-syn overexpression reduces cell growth. Stable N27 cells were 
grown in 96 well plates and treated with PonA for 72h before cell viability was 
assessed. (A) 25 µl MTT (5 mg/mL in PBS) were added directly to the wells 
containing 100 µl media. Optical density was determined by measuring 
absorbance at end point 560. (B) Cells were washed with PBS before Calcein AM 
was added. Fluorescence (Ex/Em 494/520) was measured 1h after incubation in 
dark. Data represent Mean ± SEM, n=3-4 independent experiments, student t-test. 
*p<0.05.   
  
 
3.3.3. 48h α-syn overexpression forms protein aggregation whilst   
inducing blockade of autophagy flux 
Alongside with mitochondrial fragmentation and dysfunction, a distinctive feature of 
α-syn overexpression is the accumulation of puncta in α-syn staining. To confirm the 
formation of protein aggregation, proteinase K (PK) digestion was performed. As 
seen in Fig 3.9A & B, 48h after induction, α-syn aggregates(green puncta) were 
readily detectable in cells with inducible α-syn but not in cells with empty vector 
control. It’s worth noting that the majority of the puncta stain disappeared after PK 
digestion, suggesting the abundance of soluble oligomeric forms of the protein. Non-
soluble aggregation was used in this study as an indicator for insufficient clearance 
and protein build-up. This is not a suggestion that the soluble oligomers are less 
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toxic. In fact, studies suggest the soluble forms are more mobile and they promote 
protein propagation by acting as toxic seeds (Lashuel et al., 2013). 
    Interestingly, increased numbers of what appeared to be vacuoles were also 
observed in cells overexpressing α-syn, as highlighted by the yellow arrows (Fig 
3.9C). To confirm whether these black circular structures were indeed vacuoles, 
TEM was used. Not only did these EM images reveal vacuoles in these cells (yellow 
arrows), they also indicated that these structures were part of the machinery of the 
autophagy process because they contained remnants of organelles, including 
mitochondria (Fig. 3.9D). To further investigate the effects of α-syn on autophagy, 
N27 inducible cells were transfected with LC3-mcherry (autophagosome membrane 
marker), and immuno-stained for autophagic substrate p62 (grey) and α-syn (green, 
Fig 3.9E & F). After 48h of α-syn expression, both LC3(red)and p62puncta were 
increased, indicating a blockade of autophagy flux as both autophagy machinery 
(autophagosomes) and substrate (p62) were accumulating inside the cells (E). The 
blockade was quantified using Image J (Fig. 3.9 F). These data suggest that 
autophagy-lysosomal pathway is compromised in α-syn-expressing cells, consistent 
with previous reports (Decressac et al., 2012a, Freeman et al., 2013) 
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Figure 3.9 α-syn overexpression forms PK resistant aggregates and 
accumulation of autophagic vesicles. (A and C) Stable N27 cells grown on 
cover glass were induced with PonA for 48h, fixed and immediately proceeded to 
PK treatment for 20min at room temperature. Cells were then immunostained for 
α-syn. Representative ICC images show α-syn (green) overexpression resulted in 
proteinase K (PK) resistant puncta, which were quantified using Image J with an 
average of 30 cells were counted for each treatment group per repeat. Data 
represent mean ± SEM, analysed by student t-test, n=3 independent experiments 
*p< 0.05. (C) Among the N27 cells without PK digestion, some with α-syn puncta 
formation (as shown in A) are accompanied by accumulation of small vesicles 
appearing as black vacuoles (arrows). (D) Stable N27 cells grown in 6 well plates 
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    It’s worth noticing that there were less puncta after PK treatment, suggesting 
some of puncta were soluble oligomeric forms of the protein. Recent literature 
suggests these soluble misfolded forms are more toxic due to their mobility which 
could contribute to protein propagation in α-syn pathology. However, in this study, no 
higher bands were seen in western blot possibly because they were broken down by 
RIPA buffer during cell lysis.  
 
3.4. Discussion. 
Mitochondrial dysfunction and impaired autophagy flux represent two major 
pathogenic mechanisms in PD. After the discovery of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) as the chemical causing parkinsonism(Langston et al., 
1983), mitochondrial dysfunction mediated by blockade of the electron transport 
chain has been quite well-investigated in PD. However, a more recent approach is to 
understand the impact of mitochondrial fusion and fission, not only for PD but also 
were induced with PonA for 48h and fixed and scrapped off for TEM imaging. 
Representative EM images taken at different magnifications confirming the 
accumulation of small vesicles that presented features resembling those of 
autophagic vesicles. Scale bars as indicated. (E) Stable N27 cells were 
transfected with LC3-mcherry (autophagosome membrane marker), and co-
stained for autophagic substrate p62 (grey) and α-syn (green). An increase in both 
LC3 and p62 puncta were observed in cells with α-syn. (F) LC3 and p62 puncta 
(as shown in panel E) number per cell upon were quantified using Image J. For 
quantification, images were captured with a Nikon microscope using X100 
Objective. On average 20-30 cells were counted per treatment in each individual 
experiment, with 4 separate experiments performed. Confocal images were 
captured with Olympus Fluoview FV1200 X60 Objective. Data represent Mean ± 
SEM, analysed by one-way ANOVA, followed by Newman-Keuls post hoc test.  
*p< 0.05 Scale bar: 20μm. 
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other neurodegenerative diseases (Kandimalla and Reddy, 2016, Wang et al., 
2016b, Andreux et al., 2013b).  
    To study the effects of α-syn on mitochondrial function and morphology, I used a 
rat dopaminergic neuronal cells to generate a model with inducible expression of α-
syn. This stable cell model allowed me to observe mitochondrial fragmentation and 
dysfunction, ROS production, protein aggregation and autophagy blockade in a more 
controlled and consistent manner as compared to transient transfection. I observed 
excessive mitochondrial fragmentation and increased Drp1 levels 48h after α-syn 
induction. Functionally, these cells exhibited lower mitochondrial membrane 
potential, reduced ATP production and mitochondrial spare respiratory capacity, as 
well as increased levels of ROS. Both mitochondrial and total cellular ROS levels 
were quantified in my study. As compared to cellular ROS, the magnitude of ROS 
originating from mitochondria was less. There might be a few potential reasons for 
this observation: First, in addition to blocking the ETC resulting in the production of 
mitochondrial ROS, α-syn also induce ROS production from other non-mitochondrial 
sources. Second, the sensitivity of detecting ROS by MitoSOX may be lower than by 
DHE assay. Third, the basal mitochondrial metabolic activity of N27 cells is high and 
therefore, the “ceiling” of reaching maximal mitochondrial ROS is not very dramatic. 
Supporting this argument is the observation that rotenone, a specific complex I 
inhibitor, only induced approximately 1.5-fold higher of mitochondrial ROS as 
compared to the untreated control group.  
    In addition to mitochondrial ROS, using the extracellular flux analyser to measure 
mitochondrial respiration in live cells, I detected a reduction in mitochondrial spare 
respiratory capacity in cells with α-syn overexpression. Interesting, no other 
parameters such as basal respiration, proton leak were affected. This observation 
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could be explained by the  slow and chronic effect of overexpressing a wildtype 
protein at a toxic level as compared to a selective mitochondrial inhibitor such as 
rotenone. Changes in maximal/spare respiratory capacity are more sensitive 
indicators of mitochondrial respiration as a drop in any supply to ETC complexes can 
cause this parameter to decrease. In Chapter 4, where I measured the toxicity of a 
mutant form of α-syn, a more severe drop in spare respiratory capacity was 
observed, and other parameters such as proton leak started to change. Although at 
the time I did not get a significance due to the limited experimental animal numbers. 
    Even though I could not generate those data with differentiated neurons in this 
study, the cell model used still offered valuable information on α-syn toxicity toward 
mitochondria and autophagy flux. My findings are consistent with literature 
investigating the toxicity of α-syn using different in vitro and in vivo models (Braidy et 
al., 2014, Tanik et al., 2013, Xie and Chung, 2012). Furthermore, the observations of 
increased Drp1 translocation and levels suggest excessive mitochondrial fission is 
involved in the process. Therefore, the next question I asked was whether blocking 
Drp1-mediated fission would attenuate these abnormal features observed in these 
cells. 
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4. Blocking Drp1 is protective against 
α-syn induced mitochondrial 
fragmentation and dysfunction
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4.1. Introduction 
In the previous chapter, I confirmed mitochondrial fragmentation and dysfunction as 
a result of α-syn toxicity. These observations appeared to be mediated by excessive 
mitochondrial fission because increased levels of Drp1 was observed at the 
mitochondrial and total levels. The therapeutic strategy, therefore, is to preserve 
mitochondrial morphology and function by targeting Drp1. Over the years, 
researchers have investigated different approaches to alter mitochondrial fission and 
fusion by targeting the key set of proteins such as Fis1, Mff and MiD49/51. As 
discussed, it is more effective to block Drp1 function directly rather than these Drp1 
receptor proteins individually. In this study, Drp1 silencing via siRNA and dominant 
negative K38A transfection were both applied as complementary genetic strategies. 
However, to enhance the translational value of this study, I also used a putative 
small molecule inhibitor of Drp1, which is further described below. 
In a high throughput drug screening study for mitochondrial division inhibitors, a 
small molecule termed mitochondrial division inhibitor-1 (mdivi-1) was selected out 
of 23,000 candidates (Cassidy-Stone et al., 2008). The chemical name for mdivi-1 is 
3-(2,4-Dichloro-5-methoxyphenyl)-2,3-dihydro-2-thioxo-4(1H)-quinazolinone, and at 
least two structural components of this molecule are vital for its function toward 
mitochondrial division: an unblocked sulfhydryl moiety on the 2’-position of 
quinazolinone and limited rotation about the 3’-position nitrogen-phenyl bonds. Even 
though initially the discovery of GTPase activity was characterised in its yeast 
homolog Dmn1(Cassidy-Stone et al., 2008), its protective effects consistent with 
blocking mitochondrial fission has been reported in numerous mammalian cultured 
cells and mouse models (Cui et al., 2010a, Solesio et al., 2012, Wang et al., 2016c, 
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Rappold et al., 2014, Manczak et al., 2011, Manczak and Reddy, 2015, Reddy et al., 
2017, Grohm et al., 2012). More direct evidence of mdivi-1 blocking mammalian 
Drp1 GTPase activity has also been reported. For example, a study comparing 
different compounds with the inhibitory effects on Drp1 has confirmed the efficacy of 
mdivi-1 inhibiting approximately 50% Drp1 activity at 13µM (Numadate et al., 2014). 
A more recent study also demonstrated the inhibitory effects of mdivi-1 on the 
GTPase activity of Drp1 in mammalian cells (Manczak et al., 2019) Nevertheless, 
these studies does not eliminate the potential off-target effects of mdivi-1, a common 
observation of chemical treatments. For any study addressing the effect of blocking 
Drp1, alternative methods such us genetic inhibition of Drp1 as a complementary 
approach is necessary. 
For clinical applications, non-invasive pharmaceutical approaches are more 
practical and more acceptable by patients, in comparison to gene therapy. However, 
for research purposes, the genetic approach holds more specificity, and is better for 
confirming any effects by targeting a specific protein. Therefore, in this study, the two 
complementary approaches were both applied, side by side, to investigate the 
protective effect of blocking Drp1. For genetic approach, I used siRNA to knockdown 
Drp1 as well as a dominant-negative mutation form Drp1-K38A (HA-tagged). This 
mutation lacks GTPase activity (Smirnova et al., 2001a), and forms characteristic 
puncta inside the cells attracting wild-type Drp1, which can be used as an indication 
for transfected cells (Cui et al., 2010a). For pharmaceutical approach, mdivi-1 was 
used. More details are discussed below in section 4.4.  
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4.2. Materials and Methods  
4.2.1. Cell culture and transfections 
Stable N27 cells were grown in RPMI +10%FBS +G418 (500ug/ml) + Hygromycin B 
(200ug/ml). Plasmid only transfections were carried out using Lipofectamine 3000 
and transfections involving siRNA were carried out using jetPRIME following 
manufacturers’ instructions. More details are described in Chapter 2, Section 2.2. 
 
4.2.2. Immunocytochemistry  
Stable N27 cells were transfected with Ds-Red mito and siRNA / Drp1-K38A plasmid 
overnight and induced with PonA the next morning. 48h after, cells were fixed with 
4% PFA and stained for α-syn (1:2000, AB5038) and Drp1 (1:1000, BD 61113). 
 
4.2.3. Functional studies  
Mitochondrial membrane potential.  Stable N27 cells were treated with PonA for 
24h with/without Drp1 inhibition. They were then stained with 50nM 
tetramethylrhodamine methyl ester (TMRM) for 20 min at 37 °C. Fluorescent signal 
was analysed by BD Accuri C6 flow cytometer using FL-2 channel. For positive 
control, cells were treated with 20 μM carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone for 20 min to collapse ΔΨm, and the obtained TMRM fluorescence 
was used to set the threshold.   
Oxidative Stress Stable N27 cells were treated with PonA for 24h with or without 
Drp1 inhibition. Upon assay, 10µM DHE were added to cell culture media, incubated 
for 20 min at 37°C. H2O2 (3mM) was used as a positive control. The dye was then 
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washed away with PBS, and cells were detached by tryspin, re-suspended in 
PBS+2%FBS, and analysed by flow cytometry. Data are expressed as the 
percentage of cells with signal above threshold set by H2O2. 
Mitochondrial respiration N27 stable s were grown in XFe 96 tissue culture plate 
and induced with PonA with/without Drp1 inhibition. On the day of experiment, cell 
culture media was replaced with 175ul XF assay medium (Dulbecco’s Modified 
Eagle’s Medium with 4.5mM Glucose, sodium pyruvate, PH7.4), incubated in a 37°C 
non-CO2 incubator for at least 30min before being loaded into the analyser. 
Mitochondrial respiration was measured using the Mito-Stress Test (see Chapter 2, 
Figure 2.2) (Seahorse Biosciences Inc) as instructed by the manufacturer. 
Oligomycin (1μg/ml), FCCP (0.5μM), rotenone (1μM) and antimycin A (1μM) were 
sequentially added to cells to determine mitochondrial respiration. For normalization, 
cells were fixed with 4% PFA, followed by incubation of DAPI (80μl of 5μg/ml in PBS) 
for 10 min. For normalisation, the plate was then washed 3 time with PBS, and 
fluorescent signal of DAPI was quantified at Ex/Em 358/461 nm using the Biotak 
Synergy H1 Hybrid Reader. (For more details, see Chapter 2, Section 2.5) 
 
4.3. Results 
4.3.1. Drp1 inhibition rescues mitochondrial morphology 
As shown in the last chapter, α-syn induced multiple abnormal alterations in cells 
that might be mediated by excessive mitochondrial fission, resulting in observations 
such as fragmented and donut-shaped mitochondria as my laboratory previously 
reported in a different genetic model of PD(Cui et al., 2010a) . The decrease in 
Aspect Ratio and increase in Roundness reflects fragmentation as both of these 
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values approach 1 as the particle becomes circular. To evaluate whether blocking 
Drp1 would be protective, I firstly evaluated mitochondrial morphology by performing 
immunofluorescence. Using DsRed-Mito transfection to visualize mitochondria, I 
observed that these organelles were fragmented in cells with α-syn overexpression 
(Fig. 4.1). Roundness and Aspect Ratio were calculated with and without Drp1 
inhibition. For the genetic approach, Drp1 siRNA (Fig. 4.1) and a dominant negative 
mutation, Drp1-K38A (HA-tagged) (Fig.4.3), were applied. For the small molecule 
approach, mdivi-1 was used (Fig 4.4). 
    As shown in Fig. 4.1, Drp1 siRNA blocked mitochondrial fragmentation induced by 
α-syn efficiently, resulting in the appearance of normal and elongated mitochondria 
similar to control, while non-targeting scramble control showed mostly round, 
fragmented mitochondria (Fig. 4.1A). I then quantified mitochondrial morphology in a 
blinded manner using Image J and expressed the values as Aspect Ratio and 
Roundness (Fig. 4.1B).  
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    Drp1 knockdown efficiency was confirmed using western blot, with 10nM of siRNA 
achieving approximately 80% Drp1 reduction as compared to scrambled control (Fig. 
4.2). Drp1 protein levels were quantified using Image J and normalised to 
housekeeping control β-actin. 
 
 
 
 
Figure 4.1 Drp1 inhibition via siRNA knockdown reduces mitochondrial 
fragmentation induced by α-syn overexpression. (A). Stable N27 cells were 
co-transfected with Ds-Red mito and siRNA-Drp1 or scramble control over night, 
then induced with PonA for 48h. Representative images showing the effect of 
siRNA versus scramble control. (B &C). Quantitative measurement of 
mitochondrial morphology by Image J. Roundness: 4 × ([Area])/ (π × [Major axis]2). 
Aspect Ratio: The aspect ratio of the particle’s fitted ellipse.  Data represents the 
mean ± SEM, analysed by one-way ANOVA (n=4 or 5 with >500 mitochondria 
/group counted for each n), followed by Newman-Keuls post hoc test.  *p< 0.05. 
Scale bar: 20μm.  
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Figure 4.2 Efficiency of Drp1 siRNA confirmed by western blot.  (A). N27 
cells were transfected with siRNA-Drp1 or non-targeting scramble control for 48h 
and then collected for immunoblotting. Representative images of Drp1 levels and 
the loading control β-actin. (B). Drp1 levels were normalized to β-actin and 
quantified using ImageJ.  Data represent mean ± SEM, analysed by one-way 
ANOVA, followed by Newman–Keuls post-hoc testing. n = 4 independent 
experiments. 
 
    Next, I tested dominant negative Drp1-K38A transfection (Fig. 4.3). Because this 
mutant protein was tagged with HA and appears as small aggregates after 
transfection, I performed HA immunofluorescence to distinguish overexpressed 
mutant Drp1 from endogenous Drp1 to help identify cells expressing the mutation. 
Representative images captured using confocal microscopy shown in Fig. 4.3A 
illustrate cells with α-syn overexpression displaying small, fragmented mitochondria 
(red). However, cells with Drp1-K38A overexpression preserved tubular 
mitochondrial morphology in cells with α-syn overexpression. Mitochondrial 
morphology was quantified using using Image J and expressed as Aspect Ratio (B) 
and Roundness (C). 
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Figure 4.3 Drp1 inhibition through dominant-negative transfection reduces 
mitochondrial fragmentation induced by α-syn overexpression. (A)Stable 
N27 cells were co-transfected with dominant-negative mutation Drp1-K38A (HA- 
tagged) and Ds-Red mito, then induced with PonA for 48h before fixation. HA 
and α-syn were probed by antibodies. Representative ICC images showing 
mitochondrial morphology in Drp1-K38A expression (as characterised by Drp1 
puncta formation) cells versus α-syn overexpression alone. (B &C). Quantitative 
measurement of mitochondrial morphology by Image J. Roundness: 4 × ([Area])/ 
(π × [Major axis]2). Aspect Ratio: The aspect ratio of the particle’s fitted ellipse.  
Data represent the mean ± SEM, analysed by one-way ANOVA (n=4 or 5 
with >500 mitochondria /group counted for each n), followed by Newman-Keuls 
post hoc test.  *p< 0.05. Scale bars: 20µm   
 
    Together, consistent with the effects of siRNA knockdown, Drp1 dominant 
negative mutation also prevented mitochondrial fragmentation induced by α-syn. 
Lastly, I evaluated the protective effect of the small molecule, mdivi-1. As shown in 
Fig. 4.4,  10 µM mdivi-1 treatment for 48h protected mitochondria from being 
fragmented by α-syn. In summary, as demonstrated morphologically through images 
of immunofluorescence and quantitatively by calculating the values of Aspect ratio 
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and Roundness, all three strategies (genetically and pharmacologically) blocked 
mitochondrial fragmentation induced by α-syn.  
 
 
Figure 4.4 Drp1 inhibition by mdivi-1 reduces mitochondrial fragmentation 
induced by α-syn overexpression. (A). Stable N27 cells were transfected with 
Ds-Red mito and induced with PonA with/without mdivi-1 (10µM) for 48h before 
fixation. Representative ICC images shows that mdivi-1 treatment reduced 
mitochondrial fragmentation induced by α-syn overexpression. (B &C). 
Quantitative measurement of mitochondrial morphology by Image J. Roundness: 4 
× ([Area])/ (π × [Major axis]2). Aspect Ratio: The aspect ratio of the particle’s fitted 
ellipse.  Data represent the mean ± SEM, analysed by one-way ANOVA (n=4 or 5 
with >500 mitochondria /group counted for each n), followed by Newman-Keuls 
post hoc test.  *p< 0.05.  Scale bars: 20µm   
 
   
 
4.3.2. Drp1 inhibition rescues mitochondrial function and cell viability 
Based on the observation that blocking Drp1 protected mitochondrial morphology 
against α-syn neurotoxicity, I asked whether Drp1 inhibition would also improve 
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mitochondrial function. To this end, I evaluated multiple mitochondrial function 
parameters. The efficiency of plasmid transfection in N27 cells is below 50%, this could 
dilute the effect of Drp1 inhibition. Therefore, only siRNA knockdown and small 
molecule inhibition are used in the following experiments with the same cell model. 
First, I measured mitochondrial membrane potential (ΔΨm). As previously discussed, 
a decrease in ΔΨm is indicative of mitochondrial dysfunction. Using flow cytometry, I 
quantified fluorescent intensity of tetramethylrhodamine (TMRM) taken up by 
mitochondria in N27 cells. After 48h of induction, α-syn significantly reduced ΔΨm.
Drp1 inhibition, either mediated by gene silencing (Fig. 4.5A) or the small inhibitor 
mdivi-1(Fig. 4.5B), completely prevented this deficit. An impairment in mitochondrial
function invariably would lead to free radical production such as reactive oxygen 
species (ROS). To determine whether such ROS production would originate from 
mitochondria resulting in a higher total cellular ROS, I quantified Dihydroethidium 
(DHE, Fig. 4.5C&D) and MitoSOX Red (Fig. 4.5E&F) signals to detect cellular and 
mitochondrial ROS levels, respectively. Rotenone, a complex I inhibitor, was used as 
a positive control to generate ROS from the electron transport chain (ETC) blockade. 
Consistent with its inhibitory effect on mitochondrial function, α-syn increased ROS 
levels, an adverse effect that was blunted by Drp1 inhibition (Fig. 4.5C-F). Taken 
together, these mitochondrial studies support the negative effects of α-syn on the 
mitochondrial ETC and that blocking Drp1, whether genetically or pharmacologically, 
is protective. 
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Figure 4.5 Drp1 inhibition restores ΔΨm and reduces oxidative stress from α-syn 
overexpression. (A&B) Stable N27 cells were incubated with TMRM (50nM), and 
fluorescence intensity was analysed by flow cytometry for ΔΨm. The uncoupler agent 
carbonyl cyanide 4- (trifluoromethoxy) phenylhydrazone (FCCP, 20μM) was used as 
positive control to set up threshold. (C&D) Cellular ROS was measured by incubating 
cells with 10 μM Dihydroethidium (DHE) and analysed by flow cytometry. Signal intensity 
(AU, arbitrary unit) was expressed as % above threshold established by FCCP. (E&F) 
MitoSox red signal was measured by incubating cells with 2.5 μM working solution of the 
dye for 20min and analysed by fluorescent plate reader (Ex/Em 510/580nm). For 
normalization, cells were fixed and subsequently stained with DAPI (Ex/Em 385/461 nm), 
and relative fluorescence units (RFU) were calculated by dividing mitosox intensity 
against DAPI. Mitochondrial complex I inhibitor rotenone (50nM) was used as positive 
control to induce oxidative stress. For Drp1 silencing, stable N27 cells were transfected 
with siRNA-Drp1 or scramble control overnight, followed by PonA induction for 48hs. For 
mdivi-1 treatment, cells were co-treated with PonA and mdivi-1 (10µM) for 48h. Data 
represent the mean± SEM ., analysed by one-way ANOVA (n=4), followed by Newman-
Keuls post hoc test. *p< 0.05 ** p≤0.02, *** p<0.001 
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  To directly measure mitochondrial function, I quantified mitochondrial respiration 
using the Seahorse XFe96 Extracellular Flux Analyzer (Fig. 4.6). After 48h of 
induction of α-syn expression in the stable dopaminergic N27 neuronal cells, I 
assessed multiple mitochondrial respiration components as illustrated in Fig. 4.6A, 
with or without Drp1 inhibition (both siRNA knockdown and mdivi-1 inhibition). Fig. 
4.6B & D show that α-syn specifically reduced mitochondrial respiration and siRNA-
Drp1 or mdivi-1 blocked this deficit. 
 
 
Figure 4.6 Drp1 inhibition is protective toward mitochondrial spare respiratory 
capacity reduced by α-syn overexpression (A) As previously explained in Fig. 3.5, 
mitochondrial function in live cells was assessed by measuring oxygen consumption 
rate (OCR) using the XFe96 Extracellular Flux Analyzer. (A) Sequential injections of 
oligomycin (to inhibit oxygen consumption mediated by ATP synthase), FCCP (an 
uncoupler to induce maximal OCR), Rotenone/Antimycin (to inhibit complex I and III, 
respectively). Spare Respiratory Capacity was calculated as % = (Maximal Respiration) 
/ (Basal Respiration) × 100. (B) Representative kinetic graph showing 48h of α-syn 
overexpression impairs spare respiratory capacity, and Drp1 knockdown conferred 
protection. (C) Blocking Drp1 function using mdivi-1 was also protective. Data 
represent the mean± SEM analysed by one-way ANOVA (n=4), followed by Newman-
Keuls post hoc test. *p< 0.05 
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    Corresponding to the improved profiles of spare respiratory capacity, ΔΨm, ROS 
production and mitochondrial morphology, Drp1 knockdown also attenuated cell loss 
induced by α-syn 72h after gene induction, as assessed by using calcein assay (Fig. 
4.7). Calcein AM is a non-fluorescent cell-permeant dye that can be converted to 
green-fluorescent calcein in live cells.  
 
 
Figure 4.7 Drp1 inhibition prevents cell loss induced by α-syn 
overexpression   Stable N27 cells were transfected with Drp1 siRNA or scramble 
control overnight prior to be treated with PonA for 72h to activate α-syn 
expression.  Calcein AM was then added to the cells after washing with PBS. The 
green fluorescence was quantified using a plate reader. Data represent the mean± 
SEM., analysed by one-way ANOVA (n=4), followed by Newman-Keuls post hoc 
test. *p< 0.05. ns marked are compared to control level. 
 
 
4.3.3.   Drp1 inhibition protects synaptic mitochondrial respiration in 
vivo  
As demonstrated so far in my project, using the N27 dopaminergic neuronal cells, I 
evaluated multiple mitochondrial function parameters to determine whether blocking 
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Drp1 would confer protection against α-syn With this in vitro model, I demonstrated 
that blocking Drp1 function by using siRNA, overexpressing the dominant negative 
Drp1-K38A, and small molecule mdivi-1 in dopaminergic neuronal N27 cells with 
inducible α-syn reduced mitochondrial fragmentation (Fig4.1), preserved ΔΨm (Fig 
4.5A & B), reduced ROS production (Fig 4.5C-F), and protected mitochondrial 
respiratory capacity (Fig 4.6). Furthermore, the improved mitochondrial function 
reduced cell loss induced by α-syn at a later stage In addition to the above in vitro 
model, I also collaborated in a separate study using a rat model overexpressing 
mutant α-syn A53T via adeno-associated virus (AAV2). This mutant α-syn also 
impair mitochondrial function. In general, α-syn has been demonstrated in rodent 
models to reduce striatal presynaptic dopamine release (Chen et al., 2015, Nemani 
et al., 2010, Larsen et al., 2006, Burre et al., 2010, Garcia-Reitbock et al., 2010), and 
impair mitochondrial respiration in the striatum (Subramaniam et al., 2014).  
Together, these observations are consistent with the critical role of mitochondria in 
synaptic function(Manczak et al., 2016, Kandimalla et al., 2016). With the promising 
results from my cell culture experiments, it is important to determine the protective 
role of Drp1 inhibition against α-syn toxicity in vivo. To address whether blocking 
Drp1 improved mitochondrial function in an animal model, I isolated synaptosomes 
from the striatum of rats with stereotaxic injection of AAV2 encoding human A53T-α-
syn or GFP control with or without i.p. injections of  mdivi-1 or vehicle control 
(surgeries and injections were done by Dr. Martin Helley), One week later, striatal 
synaptosomes were isolated and measured for mitochondrial function using XFe96 
Extracellular Flux Analyzer with a method adapted from a previous study (Choi et al., 
2009b). The high sensitivity of this assay format allows measurement of 
mitochondrial respiration in relatively small quantity and thus facilitates the 
108 
assessment in specific brain regions. Of note, prior to the isolation experiments, the 
delivery and expression of AAV has been verified by immunostaining (performed by 
Martin Helley, data not shown). As seen in Fig. 4.8, one week after gene delivery (an 
early time point that induces about 50% cell death) (Bourdenx et al., 2015a), A53T-α-
syn significantly impaired maximal rate of mitochondrial respiration as compared to 
the control group, resulting in reduced spare respiratory capacity. This set of data 
has recently been published (Bido et al., 2017c), in which I served as a co-author.  
Figure 4.8 Drp1 inhibition by mdivi-1 attenuates mitochondrial dysfunction in 
isolated synaptosomes A. Adult Sprague Dawley rats (6 weeks old) were 
stereotaxically injected with AAV2 encoding either human α-syn-A53T or GFP 
control in the substantia nigra in the absence or presence of mdivi-1 (20mg/kg 
twice daily i.p. injection). One week after gene delivery, striatal synaptosomes 
were processed and oxygen consumption rate (OCR) was measured using the 
XFe96 Extracellular Flux Analyzer. Sequential injections of oligomycin (to inhibit 
oxygen consumption mediated by ATP synthase), FCCP (an uncoupler to induce 
maximal OCR), Rotenone/Antimycin (to inhibit complex I and III, respectively). 
B.Values obtained from (A) were then used to calculate Spare Respiratory 
Capacity as a % = (Maximal Respiration)/(Basal Respiration) × 100  Data represent 
means ± SEM of 5 five animals per group (except for the GFP+mdivi-1 group, n = 
3), Statistical analysis was performed using two-way ANOVA, followed by Tukey 
multiple comparison test  (*p < 0.05 compared A53T groups with or without mdivi-
1). (Bido et al., 2017c)
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    So far in this study, I’ve been focusing on the effect of Drp1 in s α-syn-induced 
mitochondrial toxicity. Cell culture results confirmed the hypothesis that α-syn 
overexpression results in mitochondrial fragmentation and dysfunction and blocking 
the fission protein Drp1 provides rescuing effect. The collaboration project working 
with the mutant form of α-syn further confirms the finding in rats. Together, these 
data highlight the effectiveness of blocking Drp1 via the mitochondrial pathway. 
 
4.4. Discussion 
In this chapter, I focused on the protective effect of blocking Drp1. In stable 
dopaminergic neuronal cells with inducible expression of α-syn, reducing Drp1 
function genetically (Drp1 knockdown and overexpression of Drp1-dominant 
negative) and pharmacologically (mdivi-1 treatment) attenuated the negative impacts 
of α-syn on mitochondrial morphology and function (membrane potential, reactive 
oxygen species, respiration and spare respiratory capacity (SRC). As discussed, a 
reduction in SRC leads to energy crisis when energy demand exceeds the supply 
ability of mitochondria and SRC has been considered as a major factor that defines 
the survival of the neuron (Choi et al., 2009a). Together, these results support the 
hypothesis that α-syn induces mitochondrial fragmentation and dysfunction through, 
at least partially, a Drp1-dependent mechanism. This topic has been discussed and 
debated in the field, partly because of some conflicting data between previous 
studies (Gui et al., 2012, Kamp et al., 2010). A significant difference between my 
model and those from other laboratories is the utilisation of the inducible cell line to 
keep α-syn expression at relatively lower and more consistent levels compared to 
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transient transfection. Additionally, I believe I used multiple complementary 
approaches to confirm my results. For example, I used two genetic and one chemical 
strategies to block Drp1 function. I measured multiple parameters of mitochondrial 
function, in addition to morphology.  
    Relevant to my project, my laboratory collaborated with another group in France 
and together we recently published data demonstrating that intraperitoneal injection 
of mdivi-1 reduced neuropathology induced by α-syn-A53T in rats (Bido et al., 
2017a). We reported that mdivi-1 improved locomotor function and reduced nigral 
dopaminergic neuronal death. Intriguingly, mdivi-1 also significantly reduced α-syn-
Ser219, a phosphorylated form which correlates to increased protein aggregation. 
Consistently with this observation, we also observed mdivi-1 reduced proteinase K-
resistant α-syn. Together, these data suggest that blocking Drp1 function results in 
the reduction of formation of the toxic species of α-syn and protein aggregation. 
However, the underlying mechanism that provided these observations remained to 
be established. Because autophagy plays a major role in removing misfolded and 
aggregated proteins, it is possible that Drp1 inhibition also plays a role in autophagy. 
Given that I have already demonstrated in my N27 stable cell line that α-syn blocks 
autophagy (Chapter 3, Fig. 3.9), I decided to investigate the effect of blocking Drp1 
on autophagy flux and protein aggregation, which is the topic in the next chapter.  
 
 
 
 
111 
 
 
 
 
 
 
 
 
 
112 
 
5. Drp1 inhibition is protective against 
impairment of autophagy flux induced by 
α-syn
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5.1. Introduction 
Autophagy plays a critical role in removing misfolded proteins, including α-syn (Webb 
et al., 2003a, Cuervo et al., 2004, Lee et al., 2004). Therefore, impairment in 
autophagy leads to accumulation of α-syn, which further exacerbating the blockade 
of autophagy as demonstrated cell culture and animal models (Winslow et al., 
2010b, Ebrahimi-Fakhari et al., 2011, Yu et al., 2009, Chen et al., 2015, Bido et al., 
2017a), thus creating a bidirectional positive feedback loop of neurotoxicity (Xilouri et 
al., 2016). Although still a topic of debate, a general assumption is that monomeric 
forms of α-syn can largely be degraded by the UPS, while the oligomeric and 
aggregated forms of the protein, like other longer-lived macromolecules, mostly rely 
on autophagy-lysosome pathway for degradation (Ji and Kwon, 2017). This is based 
on the functional property and pattern of each pathway. Therefore, the formation of 
α-syn aggregation could be linked to lack of autophagy, as suggested in recent 
literature (Winslow and Rubinsztein, 2011, Sato et al., 2018).  
    In addition to mitochondrial dysfunction, my data in Chapter 3 indicate that 
autophagy flux is impaired in my stable N27 dopaminergic neuronal cell model, as 
evidenced by an accumulation of LC3 and p62 puncta in α-syn overexpressing cells. 
Additionally, I observed the formation of PK resistant α-syn puncta after 24h of α-syn 
overexpression in N27 stable cells. My laboratory recently demonstrated that 
pharmacological blocking of Drp1 dramatically reduced α-syn aggregates in nigral 
DA neurons of rats overexpressing α-syn (Bido et al., 2017b). However, it was not 
determined whether such protective effect was mediated through the autophagy 
pathway. Taken together, therefore, it is critical to investigate whether blocking Drp1, 
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in addition to preserving mitochondrial function, could also have a protective role 
towards autophagy.  
    Commonly, studies use LC3-II, the autophagosome membrane protein, as an 
indication for autophagy change (Afeseh Ngwa et al., 2011). However, LC3-II level 
(or the number of autophagosome and autolysosome levels collectively) alone is not 
sufficient to determine the state of the autophagy flux. As autophagy is a dynamic 
process, the number of autophagosome is determined by both upper (induction) and 
lower (degradation) streams of the flux. Therefore, the increase of LC3-II level could 
be from increased induction or disturbed degradation, or a combination of both. In 
order to more fully evaluate whether autophagy is blocked, it is important to combine 
LC3 quantification with an autophagy substrate such as p62 or ubiquitin. In the 
situation of increased autophagy induction, LC3-II level would increase but not p62, 
whereas the blockade of lysosomal degradation would result in the increase of both 
markers. In fact, p62 would be a more reliable marker for quantifying autophagy 
blockade as the increase in p62 is a direct result from disrupted autophagy. Two cell 
line models were used in this chapter. The same stable N27 cells were used for 
direct association of autophagy and puncta formation in the cell, and for correlation 
of mitochondrial dysfunction and autophagy. To more directly monitor autophagy flux 
in the present study, I utilized the autophagy reporter HeLa cells with stable 
overexpression of mRFP-GFP-LC3 (kindly provided by Dr. Shouqing Luo, Plymouth 
University). These cells were designed to monitor autophagy flux(Kimura et al., 
2007). The ratio of autophagosome against autolysosome obtained from the HeLa 
cells provides information that cannot be measured directly in N27 cells.  
 
5.2. Materials and Methods 
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5.2.1. Cell culture and transfection 
Stable N27 cells were maintained in selective media that contains RPMI +10% FBS 
+ G418 (500 µg/ml, Invitrogen) + Hygromycin B (200 µg/ml) 
Hela autophagy reporter cells were maintained in selective media with DMEM+ 
10%FBS +G418 (100 µg/ml). This cell line is stably transfected with a construct 
containing RFP-GFP-tagged LC3 (see Fig. 5.2A) and have autophagosome puncta 
labelled with both green and red signal simultaneously. The GFP signal is pH 
sensitive whilst the RFP signal is pH stable. When autophagosomes fused with the 
acidic lysosomes, the low pH quenches the GFP signal, leaving only the red signal. 
This allows for the distinction between autophagosomes (yellow-GFP and RFP 
merged), and autolysosomes (red-RFP only), a more detailed and insightful way to 
monitor autophagy blockade. 
Plasmid transfection Stable N27 cells were transiently transfected with LC3-cherry 
plasmid, and Hela cells were transfected with α-syn plasmid using lipofectamine 
3000 following manufacturer’s protocol. 
Drp1 knockdown 10nM of Dharmacon SMARTpool siGENOME DNM1L siRNA (Rat 
for N27 cells and Human for Hela cells) or non-targeting scramble control were 
added to cell suspension upon plating.  
 
5.2.2. PFF treatment 
α-syn monomers were obtained from the Michael J. FOX Foundation, and the 
generation of PFF was performed by shaking at 1,000 RPM for seven consecutive 
days at 37°C according to manufacturer’s protocol (more details can be found in 
Chapter 2, Section 2.7). Upon use, one aliquot was diluted into 0.1mg/mL using 
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sterile dPBS and sonicated with a Fisher Scientific 120 Sonic Dismembrator with CL-
18 microtip (30 X1s pulses, 20% power). 10µg/ml sonicated PFF were added the 
Hela cells grown in 6-well plates. 
 
5.2.3. Quantification analysis 
Puncta quantification For puncta quantification, images taken at 60X for individual 
channels (in tif. format) were imported into Image J and analysed using objective 
counter.  
Western blot N27 stable cells were induced with PonA for 48h with or without Drp1 
inhibition. Upon experiments, cell pellets were collected and lysed with RIPA buffer 
plus proteinase inhibitors, homogenised on ice, and supernatants were loaded on to 
a 12% SDS-PAGE for separation and transferred to a PVDF membrane. After 
blocking with 2.5% skin milk, membranes were incubated in primary antibody 
solutions at 4C overnight: anti-p62 (1:1000, MBL PM045), anti-Drp1 (1:2000, BD 
61113), anti-β-actin (1:10,000, Sigma A2228). 
Proteinase K digestion N27 cells were grown on glass coverslips coated with poly-
D-lysine. Freshly fixed cells were washed with PBS 2X, and incubated with 
proteinase K (0.34U/ml) for 20 min at room temperature with shaking. Cells were 
then washed with PBS and proceeded to immunostaining for α-syn.  
 
5.3 Result 
5.3.1 Drp1 inhibition protects autophagy flux in stable N27 cells 
As discussed above, autophagy is a primary pathway by which misfolded proteins 
such as α-syn are removed (Webb et al., 2003a, Cuervo et al., 2004, Lee et al., 2004). 
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One possible mechanism by which Drp1 inhibition reduced protein aggregation is by 
improving autophagic flux. Because LC3-II is selectively associated with 
autophagosomes, LC3-II or LC3-decorated vesicles has been widely used to indicate 
autophagosome levels or contents in cells (Klionsky, 2005).The levels of p62 as a 
selective autophagy substrates inversely correlate with autophagic flux (Bjorkoy et al., 
2005). To test the hypothesis Drp1 inhibition would attenuate autophagic impairment 
induced by α-syn, I quantified the levels of LC3-II and p62 levels in the N27 cells with 
inducible α-syn expression. To achieve this objective, I co-transfected N27 cells with 
LC3-cherry plasmid plus either siRNA-Drp1 or scramble control (an overexpression of 
LC3 was necessary to facilitate quantification of autophagy due to low expression of 
LC3 in these neuronal cells). As seen in Fig. 5.1A & B, α-syn significantly increased 
the number of LC3 puncta, supporting accumulation of autophagosomes. I also 
observed an increase in p62 puncta levels, indicating a blockade of autophagy (Fig. 
5.1A & B). The alterations in p62 levels were also assessed using immunoblotting 
(Fig. 5.1C). Together, these data suggest that autophagy-lysosomal pathway is 
compromised in α-syn-expressing cells, consistent with previous reports (Freeman et 
al., 2013, Decressac et al., 2012b). The accumulation of these autophagic proteins, 
however, was significantly attenuated by siRNA-Drp1 (Fig. 5.1A-C), suggesting that 
Drp1 inhibition restores autophagy-lysosomal activity or autophagic flux.  
Protein aggregation is a common pathological feature of α-syn. In our cell model 
proteinase-K resistant α-syn aggregates were detectable two days after gene 
induction (Fig. 5.1D & E). Knocking down Drp1 with siRNA drastically reduced such 
protein aggregation (Fig. 5.1D & E). This genetic approach provided data consistent 
with our previous publication where α-syn-A53T accumulation in rats was 
significantly reduced by mdivi-1 (Bido et al., 2017a) 
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Fig 5.1 Drp1 inhibition attenuates autophagic blockade and protein 
aggregation in dopaminergic N27 neuronal cells with inducible α-syn. (A) 
Stable N27 cells were co-transfected with LC3- LC3-cherry with and siRNA-Drp1 or 
scramble control, then induced with PonA for 48h. Cells were then fixed and 
immunostained for α-syn and p62. Representative ICC images demonstrate that the 
effect of Drp1 siRNA (10nM) transfection reduced on both LC3 (red) and p62 (grey) 
puncta versus cells overexpressing α-syn alone or with siRNA scramble. (B) 
Quantification of LC3 puncta and p62 puncta (as shown in A) number using Image J. 
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Images for quantification were captured using a Nikon ECLIPSE TE2000-U 
microscope, with 100x objective. On average 20-30 cells were counted per treatment 
in each individual experiment, with 4 separate experiments performed.  C Stable N27 
cells were transfected with siRNA-Drp1 or scramble control, then induced with PonA 
for 48h.Cells were then harvested, lysed with RIPA buffer, and separated by SDS-
PAGE. Blots were probed as indicated. Data represent mean ± SEM (D) Stable N27 
cells were induced with PonA for 48h, fixed and immediately incubated with 
proteinase-K (PK) for digestion. Drp1 and α-syn were then probed with antibodies. 
Representative images show protein aggregation upon α-syn overexpression with or 
without Drp1 inhibition by siRNA. Confocal images captured with Olympus Fluoview 
X60 Objective. (E) Proteinase-K resistant α-syn puncta number was counted using 
Image J, on average 30 cells were counted for each treatment group per repeat. 
Data represent mean ± SEM, analysed by one-way ANOVA, n=3 independent 
experiments, followed by Newman-Keuls post hoc test. *p< 0.05. Images for 
quantification were captured with a Nikon ECLIPSE TE2000-U microscope, with 
100x objective, on average 20-30 cells were counted per treatment in each individual 
experiment, with 4 separate experiments performed. Data represent mean ± SEM, 
analysed by one-way ANOVA, followed by Newman-Keuls post hoc test.  *p< 0.05. 
ns(non-significant) marked are compared to control levels. Scale bar: 20μm.   
 
 
5.3.2 Drp1 inhibition protects autophagy flux in HeLa autophagy reporter cells 
Although the data presented in Fig. 5.1 support the role of Drp1 in autophagy, to more 
directly monitor autophagy flux in my study, I utilized the autophagy reporter HeLa 
cells. These cells were designed to monitor the process of autophagosome fusing with 
lysosome during autophagy (as shown in Fig.5.1Aa) with stable overexpression of 
mRFP-GFP-LC3 (Fig. 5.2Ab). mRFP-GFP-LC3 vesicle analysis allows me to monitor 
autophagosome synthesis and autophagosome-lysosome fusion by labelling 
autophagosomes (green and red) and autolysosomes (red), since the low lysosomal 
pH quenches the GFP signal. Previously, α-syn was shown to impair autophagic flux 
with increased autophagosome accumulation and reduced autophagosome-lysosome 
fusion (Freeman et al., 2013). To investigate whether blocking Drp1 would improve 
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autophagy flux impaired by α-syn, I co-transfected these autophagy reporter cells with 
wild type human α-syn in the presence or absence of siRNA-Drp1 or siRNA-scramble 
control (Fig. 5.2B). After 48h, cells were immunostained for α-syn and the number of 
autophagosomes and autolysosomes were quantified in these immunoreactive cells 
in a blinded manner. As demonstrated in Fig. 5.2C & D, Drp1 knockdown, but not 
scramble control, significantly attenuated autophagosome accumulation and 
enhanced autolysosomal levels in the cells with α-syn overexpression, indicating that 
Drp1 knockdown alleviates autophagic impairment induced by α-syn.  
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Figure 5.2 Drp1 knockdown prevents autophagy flux impairment induced by 
transfected α-syn in the autophagy reporter cells..  (A) Schematic diagram 
illustrating the autophagy flux pathway and b the construct used to create the mRFP-
GFP-LC3 stable reporter HeLa cells. With this cell model, autophagosomes appear 
yellow due to the colocalization RFP and GFP signals. Red signal indicates the flux 
is functional because the green signal is quenched by the acidic environment of the 
lysosome, which fuses with autophagosome. (B) Hela cells were co-transfected with 
α-syn-wild type plasmid and siRNA-Drp1, using jetPRIME® (Polyplus). (C) 
Quantification of autophagosome and autolysosome number upon α-syn 
overexpression with or without Drp1 knockdown using ImageJ.  The numbers of 
autophagosomes (green vesicles) and autolysosomes (red vesicles minus green 
vesicles) were counted and analysed using ImageJ. Glass coverslips were then 
mounted onto slides with Prolong Diamond anti-fade mounting reagent and imaged 
with a Leica LAS SP8 using 60x objective. Data represent the mean ± SEM, n=3 
independent experiments. Analysis done by one-way ANOVA, followed by the 
Newman--Keuls post hoc test. *p< 0.05. Scale bar: 20μm.   
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    Gene silencing efficiency was confirmed using western blot, with 10nM of siRNA 
achieving over 75% knockdown compared to scrambled control (Fig 5.3).  
Figure 5.3 Drp1 knockdown efficiency in Hela cells. (A) HeLA cells were 
transfected with siRNA-Drp1 or non-targeting scramble control for 48h and then 
collected for immunoblotting. Representative images of Drp1 levels and the 
loading control β-actin (B) Drp1 levels were normalized to β-actin and quantified 
using ImageJ. Data represent the mean ± SEM, n=4 independent experiments. 
Analysis done by one-way ANOVA, followed by the Newman--Keuls post hoc test. 
*p< 0.05, ns marked are compared to control group.
    Using another genetic approach to reduce Drp1 function, I transfected cells with 
the mutant Drp1-K38A dominant negative (Fig. 5.4). In cells with Drp1-K38A 
expression as evidenced by immunostaining of the HA-tag, autophagy flux was 
significantly improved despite the co-transfection of α-syn.  
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Figure 5.4 Dominant negative mutation Drp-K38A prevents autophagy flux 
impairment induced by transfected α-syn in the autophagy reporter cells.  A. 
As a complementary approach to siRNA knockdown, Hela cells were co-
transfected with α-syn-wild type plasmid and HA-tagged Drp1- K38A using 
Lipofectamine 3000. After 48h, cells were fixed and immunostained with anti-α-syn 
(Millipore AB5038) and anti-HA (Roche 12CA5) Cover glasses were then mounted 
onto slides with Prolong Diamond anti-fade mounting reagent and imaged with a 
Leica LAS SP8 using 60x objective. (Cyan: α-syn, Gray: HA) Scale bar: 20μm.  B 
Quantification of autophagosome and autolysosome number was performed using 
Image J. Data represent the mean ± SEM, n=3 independent experiments. Analysis 
done by one-way ANOVA, followed by the Newman--Keuls post hoc test. *p< 0.05, 
ns marked are compared to control group.  
 
    As a comparison to genetic approaches, I also assessed the effects of the small 
molecule mitochondrial division inhibitor-1 (mdivi-1) in this study. Fig. 5.5 
demonstrate that mdivi-1 also protected against α-syn-induced autophagy blockade. 
 
 
 
 
124 
 
 
 
Figure 5.5 Drp1 inhibition with mdivi-1 prevents autophagy flux impairment 
induced by transfected α-syn in the autophagy reporter cells.  (A) Hela cells 
were transfected with α-syn-wild type as described above and treated with mdivi-1 
(10µM) 24h later. Next day, cells were fixed and immunostained for α-syn 
(Millipore AB5038), followed by Alexa Fluor 633 anti-rabbit secondary. Cover 
glasses were then mounted onto slides with Prolong Diamond anti-fade mounting 
reagent and imaged with a Leica LAS SP8 using 60x objective (Cyan: α-syn, Gray: 
HA, scale bar: 20 μm) Scale bar: 20μm. (B) Quantification of autophagosome and 
autolysosome number was performed using Image J. Data represent the mean ± 
SEM, n=3 independent experiments. Analysis done by one-way ANOVA, followed 
by the Newman--Keuls post hoc test. *p< 0.05, ns marked are compared to control 
group.  
 
    Human α-syn preformed fibrils (PFF) has been used in recent years to induce the 
release of exosomes and the spread of α-syn from one cell to another in vitro (Freundt 
et al., 2012, Volpicelli-Daley et al., 2014, Luk et al., 2012) and in vivo (Luk et al., 2012). 
Small seeds of PFF generated from recombinant α-syn can be endocytosed by 
neurons where it recruits endogenous α-syn to form phosphorylated and insoluble 
aggregates (Volpicelli-Daley et al., 2014). I obtained α-syn monomers from the 
Michael J. FOX Foundation and generated PFF according to the accompanying 
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protocol. With transmission electron microscopy (TEM), I confirmed the morphology 
and size of PFF and its sonicated form (Fig. 5.6A). Using the autophagy reporter HeLa 
cells, I confirmed that PFF blocked autophagy flux and siRNA-Drp1 attenuated this 
impairment (Fig. 5.6B & C). Furthermore, this treatment also reduced α-syn protein 
aggregation. In combination, in a human cell model designed to monitor autophagy 
flux, the genetic and pharmacological data provide strong evidence that blocking Drp1 
alleviates the negative impact of α-syn on autophagy flux and therefore supporting a 
novel protective mechanism of Drp1 inhibition. 
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Figure 5.6 Drp1 inhibition prevents autophagy flux impairment induced by pre-
formed fibril (PFF) α-syn in the autophagy reporter cells. (A) EM images 
confirming the formation and sonication results of PFF  (B) Sonicated PFF (8 
µg/well) was added to HELA cell culture for 72h, cells were then washed thoroughly, 
fixed and immunostained for α-syn. Representative images showing addition of PFF 
blocking autophagy flux in Hela cells and siRNA-Drp1 knockdown (10nM) improves 
autophagy flux. Hela cells were plated onto cover glass in 6-well plates, knockdown 
using jetPRIME. The next day media was changed and sonicated PFF (8μg/well) 
was added to the cells and incubated for 72h. Drp1 knockdown in the cells is 
confirmed by ICC staining using Drp1 antibody (BD 61113). (C) Quantitative analysis 
of autophagosome and autolysosome numbers along with protein aggregation 
formation. Puncta numbers were counted using image J. On average 30 cells were 
counted per treatment group for each repeat. Data represent the mean ± S.E., n=3/4. 
Analysis done by one-way ANOVA, followed by the Newman--Keuls post hoc test. 
*p< 0.05. Scale bar: 20μm.                           
127 
 
 
5.4 Discussion 
In this chapter I evaluated the protective effects of Drp1 inhibition mediated through 
autophagy. Between two cell models, rat N27 dopaminergic neuronal cells with 
inducible expression of α-syn and human autophagy reporter HeLa cells, reducing 
Drp1 function genetically (Drp1 knockdown and overexpression of Drp1-dominant 
negative) and pharmacologically (mdivi-1 treatment) attenuated autophagy flux 
blockade induced by α-syn.  
    One major rationale for using the N27 cells for this study was to maintain 
consistency by using the same neuronal cell model as other studies in chapters 3 
and 4. The fact that these are dopaminergic neuronal cells also made them more 
ideal to model the cell type affected in PD. To monitor autophagy flux in these cells, I 
quantified the levels of LC3 and p62. However, because the expression of 
endogenous LC3 N27 cells was low, I had to perform transient transfection of LC3-
cherry plasmid. As with other transient transfections, maintaining a consistent level 
of protein expression between experiments could be challenging and there was a 
concern that too high level may affect the outcome of the study. The HeLA 
autophagy reporter cells provided by Dr. Shouqing Luo allowed me an additional 
opportunity to evaluate the protective effects of blocking Drp1 against impaired 
autophagy induced by α-syn. With stable overexpression of mRFP-GFP-LC3, these 
cells were designed specifically to monitor autophagy flux (Kimura et al., 2007). I 
believe that adding this human cell model to my N27 rat cells would make my study 
more translational and scientifically more rigorous. The consistent results that I 
obtained between these two cell lines indicate that the protective effects of blocking 
Drp1 is reproducible across cell lines, regardless of human or rat origin as well as 
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neuronal or non-neuronal cells. As a fundamental process for cell survival, 
autophagy flux is a universal and highly conserved process across different cell 
types (King, 2012). Although not a neuronal cell line, HeLa cell model is a very quick 
and useful tool to confirm and provide more information on α-syn induced autophagy 
blockade.  In addition, different cell types have been reported to contribute to α-syn 
aggregation and propagation in PD models (Braak et al., 2007, Breen et al., 2019), 
indicating rescuing autophagy blockade in other cell types can also be beneficial. 
Therefore, confirming the protective effect of blocking Drp1 toward autophagy in a 
non-neuronal cell line would further strengthen the potential of targeting this protein 
as a therapeutic strategy. 
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6. Discussion and Conclusions
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6.1. General discussion 
Perhaps the most investigated PD-linked gene to date is SNCA. While mutation in this 
gene is rare, the SNCA locus is a significant variant factor for PD development(Lill et 
al., 2012). Missense mutations as well as gene duplications and triplications of SNCA 
have been identified in familial PD (Polymeropoulos et al., 1997b, Appel-Cresswell et 
al., 2013b, Zarranz et al., 2004b). The fact that increasing the gene dosage of SNCA 
by two to three fold can also cause PD (Singleton et al., 2003b) is significant, because 
it indicates that elevated wild-type -syn alone is sufficient to cause the disease. α-
syn is also a key factor of idiopathic PD and present in Lewy bodies, which are 
abnormal proteins commonly observed in PD (Spillantini et al., 1998). Pathogenic 
mechanisms associated with α-syn have therefore been at the forefront of the PD 
research and multiple high-profile discoveries have greatly contributed to the 
understanding of disease pathology. It is not surprising, therefore, that targeting α-syn 
as a therapeutic strategy for PD has been intensively pursued. Since its discovery as 
the first familial link to PD over two decades ago, this protein has been associated with 
multiple neurotoxic mechanisms, such as mitochondrial dysfunction and impaired 
autophagic flux. These two mechanisms are highly relevant to my project. 
    Mitochondria are essential to the maintenance of normal neuronal function and 
viability through regulation of key processes such as energy production, calcium 
homeostasis, intracellular transport, neurotransmitter release and reuptake 
(Hollenbeck, 2005, Ly and Verstreken, 2006). Studies in recent years have also 
highlighted that mitochondria are highly dynamic organelles prompting the term 
“mitochondrial dynamics”, which refers to the processes of fission, fusion and 
movement along microtubules that allow mitochondria to relocate to axons, dendrites 
and terminals (Chen and Chan, 2009). Accumulating evidence indicates that perturbed 
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mitochondrial dynamics is a pathogenic mechanism in a number of neurodegenerative 
diseases, and manipulating mitochondrial fission and fusion has been considered as 
a potential novel mitochondrial therapy in recent years (Wang et al., 2016a, Archer, 
2013, Andreux et al., 2013a). Within this context, blocking dynamin-related protein 1 
(Drp1) is the most highly pursued strategy to block mitochondrial fission, because Drp1 
can bind to multiple downstream fission proteins to sever mitochondria, as illustrated 
in Fig. 1.5. Using the MPTP and Pink1-KO mouse models as in vivo PD models of 
mitochondrial dysfunction, we have demonstrated that blocking Drp1 genetically and 
pharmacologically (mdivi-1) is protective against synaptic dysfunction and 
neurodegeneration (Rappold et al., 2014). In a more recent study, we demonstrated 
that mdivi-1 improved mitochondrial function and reduced protein aggregation induced 
by α-syn-A53T in rats (Bido et al., 2017a). 
Mdivi-1, as discussed in Chapter 4, was discovered in a high throughput drug 
screening study from a chemical library of 23,000 candidates as an inhibitor of Drp1 
(Cassidy-Stone et al., 2008). It is worth noting, however, that a recently study 
questioned whether this inhibitor was specific for Drp1 and these authors reported 
that mdivi-1 had a reversible mitochondrial complex I inhibitory property (Bordt et al., 
2017b). In that study, Drp1-GTPase activity was assessed using recombinant human 
Drp1, and no more than 25% of GTPase activity inhibition was achieved using up to 
100µM mdivi-1. The results of this study are in contrast with another study 
(Numadate et al., 2014). This latter study provided direct evidence of mdivi-1 in 
blocking Drp1 function with a Ki50 of 13µM. In addition, many different laboratories 
have reported a rescue effect of mdivi-1 on mitochondrial fragmentation in different 
disease models as recently reviewed (Smith and Gallo, 2017a). As pointed out by 
Smith & Gallo, the dose of mdivi-1 used by Bordt et al. was quite high. Many groups 
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including our laboratory have seen the protective effect of the molecule at lower 
doses in different in vitro models. In our previous study (Cui et al., 2010a), a clear 
dose effect of this small molecule was noticed, with a dose as low as 5 μM conferred 
protection but a neurotoxic effect was observed at 30 μM. To date, more than 100 
primary publications (Pubmed search) have reported the protective effect of mdivi-1 
in a wide-range of experimental model and the observation of elongated 
mitochondria is widely observed. Therefore, although more studies are required to 
provide more direct evidence regarding the link between mdivi-1 and Drp1, available 
evidence suggests that mdivi-1 does block mitochondrial fission and confers striking 
protective effects across multiple disease models (Smith and Gallo, 2017a) 
    Autophagy has been reported to play a critical role in removing misfolded and 
aggregated α-syn (Webb et al., 2003a, Cuervo et al., 2004, Lee et al., 2004). 
Inhibition of autophagy flux induced α-syn, therefore, leads to accumulation of this 
toxic protein, which further exacerbating the blockade of autophagy as demonstrated 
cell culture and animal models (Winslow et al., 2010b, Ebrahimi-Fakhari et al., 2011, 
Yu et al., 2009, Chen et al., 2015, Bido et al., 2017a), thus creating a bidirectional 
positive feedback loop of neurotoxicity (Xilouri et al., 2016). Strikingly, recent data 
from my laboratory and others show that blocking Drp1 is capable of reducing 
protein aggregation. Reddy and colleagues, for example, reported than crossing 
Drp1+/- mice with either the AβPP (Tg2576) or the Tau P301L transgenic mouse 
models of (AD) reduced accumulation of toxic proteins in these animals (Manczak et 
al., 2016, Kandimalla et al., 2016). We recently demonstrated that pharmacological 
blocking of Drp1 dramatically reduced α-syn aggregates in nigral DA neurons of rats 
overexpressing α-synclein-A53T (Bido et al., 2017a). Together, these results suggest 
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that one possible mechanism by which blocking Drp1 reduces protein aggregation is 
through an improvement in autophagic function. 
    Given the well-established function of Drp1 in mitochondrial fission and its potential 
role in autophagy, my project evaluated the protective effects of Drp1 inhibition 
mediated through these two mechanisms. I obtained data showing that blocking Drp1 
improved both mitochondrial function and autophagic flux in experimental models of 
α-syn. Using the rat N27 dopaminergic neuronal cells with inducible wild-type human 
α-syn, I observed excessive mitochondrial fragmentation and increased Drp1 levels 
48h after gene induction. Functionally, these cells exhibited lower mitochondrial 
membrane potential, reduced ATP production and mitochondrial spare respiratory 
capacity (SRS), as well as increased levels of mitochondrial reactive oxygen species 
(Chapter 3). To evaluate the protective role of Drp1 inhibition, I used three 
complementary approaches: gene silencing mediated by siRNA, overexpression of 
Drp1-dominant negative and the small molecule mdivi-1. Both morphological and 
functional defects induced by α-syn were attenuated by these strategies (Chapter 4). 
Importantly, Drp1 inhibition drastically reduced proteinase K-resistant α-syn in multiple 
cell models with overexpressing human wild-type α-syn or the treatment of 
recombinant α-syn (PFF). Based on that observation, I investigated the involvement 
of autophagy. Through a combination of stable HeLa autophagy reporter cells and 
immunostaining for LC3 and p62 in N27cells with either α-syn overexpression or 
treatment of human α-syn PFF, I observed that Drp1 inhibition abolished autophagic 
impairment induced by α-syn (Chapter 5). In combination, my novel observations 
highlight new insights that Drp1 inhibition confers neuroprotection through both 
mitochondrial and autophagy-lysosomal pathways as illustrated in Fig. 6.1. 
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Figure 6.1 Drp1 inhibition breaks the negative feedback loop created by α-syn 
overexpression. Left: α-syn overexpression disrupts mitochondrial dynamics, 
leading to mitochondrial fragmentation and dysfunction. α-syn also inhibits the 
autophagy-lysosomal pathways. Because autophagy flux is an energy dependent 
process and autophagy is important for the removal of damaged mitochondrial, 
these two important processes influence each other’s functions. Impaired autophagy 
reduces the clearance of misfolded α-syn, which accumulates inside the cells, forms 
aggregates whilst imposing more inhibition on the two mitochondrial and autophagy 
pathways. Right: Blocking Drp1 breaks the negative feedback loop by restoring 
mitochondrial function and improving autophagy flux, resulting in enhanced 
clearance of misfolded protein oligomers and reduced accumulation of protein 
aggregation. This would in turn pose less inhibition on the mitochondria and 
autophagy function. 
 
. 
 
.     
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6.2. Conclusions and future perspectives 
Mitochondrial dysfunction, impaired autophagy flux, oxidative stress and α-syn 
pathology (aggregation and spread) have all been proposed to play a dominant 
pathogenic role in PD.  Previously, our lab have reported that blocking Drp1 is 
neuroprotective in both cell (Cui et al., 2010a) and animal models of PD (Bido et al., 
2017b, Rappold et al., 2014). A complementary approach using a peptide known as 
P110 to block the binding of Drp1 to Fis1 has also been shown to be protective in the 
MPTP models (Qi et al., 2013a, Filichia et al., 2016a). However, all these previous 
studies only focused on the mitochondrial fission pathway. Using models of α-syn, 
which is relevant to familial and sporadic PD, my study provides the following novel 
observation:  Drp1 inhibition through multiple approaches (siRNA, dominant negative 
K38A transfection and mdivi-1) have consistently shown to enhance autophagy flux, 
pointing to a novel pathway involving Drp1 and autophagy. Together with 
mitochondrial function, these discoveries highlight new insights that Drp1 inhibition 
confers neuroprotection through both mitochondrial and autophagy-lysosomal 
pathways, further strengthening the therapeutic potential of targeting Drp1.  
Nonetheless further study is needed to address the following questions: 
    First, how and at what stage of autophagy flux does Drp1 inhibition has an impact 
on? Since the submission of this thesis, I have performed additional experiments to 
address this question and have included these data in the manuscript that I recently 
submitted for publication. Briefly, I transfected the autophagy reporter mRFP-GFP-
LC3 HeLa cells with siRNA-Drp1 or scramble control and then treated them with 
chloroquine to block lysosomal function, which resulted in a reduction in 
autolysosomes and an increase in autophagosomes. These alterations were 
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attenuated by Drp1 inhibition, suggesting a partial improvement in lysosomal function. 
Interestingly, the number of autophagosomes remained relatively high in the cells with 
higher levels of autolysosomal activity under Drp1 inhibition. This result suggests that 
Drp1 inhibition might also promote the formation of autophagosomes. Therefore, in 
theory, Drp1 inhibition enhances autophagy flux by increasing both the levels of 
autophagosomes and the function of lysosomes. To gain additional mechanistic 
insights into the observed higher autophagosome levels, I transfected stable N27 cells 
with siRNA-Drp1, followed by α-syn induction for two days and then cells were 
collected for immunoblotting to assess mTOR activity (which inhibits autophagy) by 
quantifying the levels of phosphor-4E-BP1, which is a downstream substrate of mTOR. 
I observed α-syn activated mTOR, and strikingly, knocking down Drp1 inhibited mTOR 
activity to an equivalent extent as rapamycin, an mTOR inhibitor (data included in the 
submitted manuscript). Together, these data provide a highly novel evidence that Drp1 
inhibition increases autophagy flux by a combination of increasing the formation of 
autophagosomes and the function of lysosomes. However, future studies are needed 
to address: (i) whether Drp1 is localized to the autophagy pathway, (ii) does Drp1 
functionally interact at an early or late stage of autophagy (or both), and (iii) whether 
Drp1 mediates its effects on autophagy through a mitochondrial dependent 
mechanism. 
    Second, given that autophagy flux could be affected by mitochondrial function, 
does Drp1 inhibition have a direct effect on autophagy or through a mitochondrial 
dependent mechanism? It could be challenging to answer this question as multiple 
pathways are interlinked and impacted by each other in the cell. The function of 
mitochondria and autophagy are not mutually exclusive and as a consequence, it 
would be difficult to distinguish whether or to what extent the effect of Drp1 on 
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autophagy is mediated through a mitochondrial independent mechanism. A potential 
approach is to use cells with minimal to no mitochondrial function to study the effect of 
Drp1 inhibition on autophagy flux. One example of such a cell model is the so called 
“Rho 0” cells, which are depleted of mtDNA. Although viable, these cells do not have 
fully functional mitochondria. If blocking Drp1 could still promote autophagy, this 
would provide evidence that Drp1 affects autophagy via a mitochondrial independent 
mechanism. 
    Third, does blocking Drp1 reduce the propagation of α-syn through exosomal 
release and therefore reduce the spread of α-syn pathology? Blockade of the 
mitochondrial electron transport chain and autophagy flux has been shown to induce 
the spread of α-syn inter-cellularly. For example, exposure of enteric neurons to 
rotenone, a mitochondrial complex I inhibitor, promotes the release of α-syn, which is 
subsequently taken up by and form aggregates in the recipient neurons (Pan-Montojo 
et al., 2012b). Emerging evidence indicates that α-syn can spread inter-cellularly 
through exosome release, primarily because of its ability to impair mitochondria and 
autophagy (Guo and Lee, 2014, Alvarez-Erviti et al., 2011). Exosomes are small 
extracellular vesicles with a typical size of 40–100 nm. Because these vesicles carry 
cargos such as mRNA and proteins, they could play a role in the spread of misfolded 
proteins such as α-syn (Chistiakov and Chistiakov, 2017). It has been demonstrated 
that impaired autophagy induces exosome-mediated α-syn spread to other neurons 
(Alvarez-Erviti et al., 2011), forming aggregates and inducing death in the receiving 
cell (Desplats et al., 2009b, Hansen et al., 2011). Based on my data, by improving 
mitochondrial function and autophagy flux, it is likely that blocking Drp1 would reduce 
exosome release. 
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    Fourth, would neuroinflammation be reduced if Drp1 function is reduced in glial 
cells such as microglia and astrocytes? The role of activated microglia in causing 
neuroinflammation by releasing molecules such as TNF-α, IL-1β and IL-6 has been 
well-documented and proposed to be involved in PD pathogenesis(Kim et al., 2013b, 
Su et al., 2008, Zhang et al., 2005b). Relevant to my study, lipopolysaccharide (LPS) 
has been reported to induce mitochondrial fission in microglia leading to 
neuroinflammation. Using primary microglia (Nair et al., 2019) and the BV2 murine 
microglial cells (Park et al., 2013), two independent studies show that LPS induces 
mitochondrial fragmentation and neuroinflammation via a Drp1-dependent 
mechanism. Blocking Drp1 using shDrp1 and mdivi-1 reduces LPS-induced release 
of pro-inflammatory molecules. In addition to microglia, astrocytes are capable of 
causing neuroinflammation (Sarkar et al., 2018) - although to a lesser extent than 
microglia. In primary mouse astrocytes and the human U373 astrocytes, manganese 
(Mn) reduces oxidative phosphorylation, increases mitochondrial fragmentation and 
neuroinflammation - especially in the presence of supplemented aggregated α-syn 
(Sarkar et al., 2018). The mitochondrial targeted antioxidant mito-apocynin was 
demonstrated to be highly protective against Mn-induced such alterations in 
astrocytes (Sarkar et al., 2018), suggesting impaired mitochondria as the cause of 
neuroinflammation. Together, these studies indicate that enhanced mitochondrial 
fission in microglia and astrocytes are linked to their production of proinflammatory 
molecules. It is important to assess the protective effects of blocking Drp1 against 
neuroinflammation in PD models.  
    To conclude, my results highlight that Drp1 inhibition confers neuroprotection 
through both mitochondrial and autophagy-lysosomal pathways. Although additional 
studies are required to fully understand the mechanism(s) by which blocking Drp1 
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improves autophagic function, the strong possibility that blocking Drp1 also reduces 
neuroinflammation and spread of misfolded toxic proteins further strengthens the 
therapeutic potential of targeting Drp1. 
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